annual report

Helmholtz Zentrum München – German Research Center for Environmental Health

At a glance: 3 research programs within the program-oriented funding (POF) framework of the Helmholtz Association of German Research Centres 760 publications (2008) 51 doctoral degrees in conjunction with various universi-ties (2008) 122 patent families 79 license agreements 1680 staff mem-bers 40 trainee positions 28 research institutes and departments 198 million euros (2008) finance volume 52-hectare research campus to the north of Munich

Helmholtz Zentrum München is a member of Germany’s largest scientific organi-zation, the Helmholtz Association of German Research Centres. With 28,000 em-ployees and an annual budget of 2.8 billion euros, its mission is to pursue long-term research objectives on behalf of government and society. The insights and knowledge gained by the Helmholtz Association help to preserve and improve the foundations of human life.

Annual Report 2008

Tailoring Drugs to Individualsp.19

Slowing Aging Processesp. 23

Boosting the Immune Systemp. 33

Regenerating Brain Cellsp. 43

Making Disease Processes Visiblep. 51

Helmholtz Zentrum MünchenResearch at the interface of health and the environment

Contents

Helmholtz Zentrum München is the German Research Center for Environmental Health. As leading center oriented toward envi-ronmental health, it investigates complex diseases which de-velop from the interaction of environmental factors, lifestyle and individual genetic disposition. Metabolic and respiratory diseases, neurodegeneration, diseases of the immune system and other chronic diseases are our main areas of research in-terest. Through a better understanding of disease mechanisms, we aim to develop innovative approaches for prevention, diag-nosis and therapy.

Contents

Dedicated to Advancing Research Looking Back at 2008Highlights Metabolism Respiratory System Immune System Nervous System Focus Spanning

Looking Ahead One Center, One Goal Research in Three Strategic Programs

Facts Technology Transfer Staff Financial Development Organizational Structure

Research Institutes and DepartmentsImprint

We are dedicated to advancing research.Young people are our scientific potential.

Postdocs and PhD students from all over the world make up half of our scientific staff. Their competence and motivation are the cornerstones of our international competitiveness. We support and mentor our junior re-searchers and thus invest in the future.

From L to R Alexander Mannes (Institute of Clinical Molecular Biology and Tumor Genetics) / Ramona Böhm (Comparative Medicine Department) / Andrea Braun (Clinical Cooperation Group »Environmental Dermatology and Allergology«) / Teresa Neumaier (Institute of Radiation Protec-tion) / Michael Telgkamp (Institute of Bioinformatics and Systems Biology) The photo was taken on the Panzerwiese across from the research campus.

The new name also documents that we are a member of the Helmholtz Association of German Research Centres and underscores our commitment to Munich as research location. At a festive event in the presence of Bavaria’s Minister President Dr. Günther Beckstein, Helmholtz Associa-tion President Prof. Dr. Jürgen Mlynek and representatives of the Federal Ministry of Education and Research (BMBF), we presented our goals and our strategy to a wide circle of partners. A further milestone was securing our financing. In 2007 and 2008 we focused our efforts on this important issue and are now in an excellent starting position to carry out our endeavors. The evaluation for the second period of program-oriented funding (POF) of the Helmholtz Association completely confirmed our successful reorientation. The Helmholtz Senate concurred with this positive assessment made by the international panel of experts. For the period from 2009 to 2013 our center will receive a total of 496 million euros as allocation for its basic operational financing. The evaluators and the Senate have thus clearly approved the strategy of the center with its focus on health research. With environmental health we associate the interaction of environmental factors, living conditions and genetic information in the context of human health as well as the development and treatment of chronic diseases such as lung diseases, diabetes or neurodegen-erative diseases. With this new focus our research center enjoys a unique position in the interna-tional research landscape. The investigation of lung diseases will be a main focus of our research work in the future. In this context, building up the Comprehensive Pneumology Center together with the Ludwig-Maxi-milians-Universität Munich (LMU) and the Asklepios Specialist Hospital in Gauting is a key as-pect of this endeavor. On November 1st we were able to establish the Institute of Lung Biology and Disease headed by Prof. Dr. Oliver Eickelberg, which together with the new Institute of Cli-

2008 was a successful and dynamic year for the strategic reorientation of the center. As of January 1st we changed our name to Helmholtz Zentrum München – German Re-search Center for Environmental Health. The renaming reflects our aim to become the world’s leading center in the field of environmental health research.

Directors’Message

nical Pneumology (the director is still to be appointed) will form the core of the new translational center for lung research. Hence, we are making a major contribution to closing the research gap of this medically and economically increasingly important disease complex. In doing so, we are ensuring that new treatment approaches will be quickly available to patients. Other main research areas will be metabolic diseases, in particular diabetes mellitus, diseas-es of the immune system and mechanisms in neurodegeneration, cancer and chronic diseases. We have made marked achievements in these fields as well. — In building up our research focus on diabetes we have made major steps forward in our cho-sen course of action. A diabetes task force is preparing the founding of two new clinical coopera-tion groups together with the university hospitals of Technische Universität München and Lud-wig-Maximilians-Universität. A junior research group studying the mechanisms of insulin resis-tance at the Institute of Experimental Genetics already began work in February. Through resolu-tions of our Supervisory Board concerning the founding of two new institutes on diabetes re-search we are in the position to achieve the required critical mass in this field, which is becoming increasingly important for public health. Our activities are paying off: In September Prof. Dr. Annette Schavan, Federal Minister of Education and Research, and the Bavarian Minister Pre-sident announced the founding of a national diabetes center located in Munich, with Helmholtz Zent rum München as coordinator. — In the competition for the new foundation of the German Center for Neurodegenerative Dis-eases in Bonn we were able to achieve a partial success due to our research focus in the field of neurodegeneration: We will participate in building up a partner location in Munich in coopera-tion with our university partner groups.

DIRECTORS’ MESSAGE

Helmholtz Zentrum München, Technische Universität München

and Ludwig-Maximilians-Universität Munich work together close-

ly. Joint appointment processes when filling institute director

positions and university chairs help to attract internationally

sought-after researchers to the science location of Munich.

— In December we signed the founding charter for a joint allergy research center together with Technische Universität München (TUM). This center will house the only chair in Germany for mo-lecular allergology and environmental research.

In conjunction with the establishment of Helmholtz Zentrum München and its strategic orienta-tion on environmental health, the Asse Mine was transferred to the area of responsibility of the Federal Office of Radiation Protection as of January 1, 2009. Since 1964, on behalf of the Federal Government, the former salt mine had been operated by the former Gesellschaft für Strahlen-forschung as research mine for the development and testing of end-storage procedures for radio-active waste. Since the middle of the nineties, preparations had been made for closing and filling the mine. The key performance indicator for a research institution is its output of scientific results. Through impressive publications in prestigious journals we demonstrated the excellence of our center again in 2008. Both the number of publications in peer-reviewed journals and the cita-tions in the scientific community in the form of impact factors have significantly increased during the past year.

Successful publications in renowned journals are also the connecting points for building up na-tional and international cooperation initiatives as well as strategic partnerships. In 2008, a whole array of new large-scale projects could be initiated at our center: — The »Helmholtz Alliance for Mental Health in an Aging Society« (HelMA), led by Helmholtz Zentrum München, brings together Germany’s leading Alzheimer and Parkinson experts in a col-laboration to investigate the causes of neurodegenerative diseases and to develop diagnostic methods and therapeutic approaches. — Within the framework of the KORA-Age project together with three other university and cli-nical partners, the long-term influence factors and consequences of multimorbidity in elderly and old people shall be investigated. — »From Disease Genes to Protein Pathways« is a new consortium project that compares pro-tein interactions in humans and in mice. The findings shall contribute to the elucidation of dis-ease-related signaling pathways and their application in the prevention and therapy of diseases. — New projects funded by the Federal Ministry of Education and Research include the creation of a mouse model to research alcoholism and two subprojects for the disease-related Competence Network Adiposity, which is striving to improve the scientific basis for the effective prevention of early obesity in children. — As part of the Roadmap for European Infrastructure funded by the European Commission, Helmholtz Zentrum München participates in three infrastructures in the fields of biosciences and medical research. Here the purpose is to build up infrastructures for phenotyping and archiving genome models in mammals, to establish biosample databases and to provide biomolecular re-sources as well as biological information. — Last not least, Helmholtz Zentrum München, together with the German Cancer Research Cen-ter (DKFZ), is initiator and coordinator of the Germany-wide »Helmholtz Cohort« in the service of health research. Two hundred thousand healthy citizens shall be included in a new, large-scale population study over a period of ten to 20 years to investigate common chronic diseases such as diabetes, cancer, cardiovascular diseases or dementia diseases. Helmholtz Zentrum München and

Helmholtz Zentrum München scientists have an above-average

publication and citation rate in renowned science journals.

In 2008, 762 publications by scientists of Helmholtz Zentrum

München were recorded in the Science Citation Index Database

of the Institute for Scientific Information (ISI), not counting 134

additional publications and books from the center.

DIRECTORS’ MESSAGE

Prof. Dr. Günther WessCEO and President

Dr. Nikolaus BlumCFO

the German Cancer Research Center will coordinate the study and plan and carry it out together with universities and other national research institutions.

To ensure the future of our center and to make an active contribution to the improvement of hu-man health and quality of life through excellent research, we rely on the high qualifications and motivation of our staff members. The expansion of our offerings to promote young researchers is of key importance to us: — Helmholtz Zentrum München’s own doctoral program offers around 300 PhD students an ex-cellent scientific environment in a wide cooperation network with universities, hospitals and other Helmholtz centers. With the establishment of an own office for PhD students and a center-wide Doctoral Students’ Day we have intensified our activities for doctoral students. — Within the framework of the junior researchers’ program in which we give young researchers the opportunity to head their own research groups, two new groups could be added. Internally, by strengthening the area of human resources development, we want to purposefully support our young employees in their career planning. — We view the anchoring of equal rights and equal opportunities for men and women to be an essential part of our corporate culture. Last year – for the second time – our center was awarded the Total E-Quality Certificate, which is granted to companies, organizations and universities who offer equal opportunity for men and women. — Furthermore, in 2008 the new alumni portal linking former staff members to the center was launched. The platform shall serve to build up a national and international network.

In 2008 we placed special emphasis on management processes. We consider the further develop-ment of two topics to be the key to the future of our center: our mission statement and corporate governance. Both are essential to successfully implement our center’s strategy and attain our in-tended objective of becoming the world’s leading center for environmental health by 2013.

The basis of our success is the excellent work and commitment of our staff, and we would like to take this opportunity to express our special gratitude to all of them. We would also like to thank the Supervisory Board and the Scientific Advisory Board for their competent accompaniment of our activities, the Federal Ministry of Education and Research and the Bavarian State Govern-ment for their confidence in us and for the allocation of funds. Many thanks also to the President of the Helmholtz Association and the office in Berlin for their active support in communicating our themes and anchoring them in the Helmholtz Association.

1. Our new name reflects our program: Helm-holtz Zentrum München – German Research Cen-ter for Environmental Health. The new name de-notes the position of the center in the research landscape.

8. Tracking down the herpes virus: With the support of the Service Platform for Monoclonal Antibodies, for the first time all proteins of the human herpes virus in infected mammalian cells are identified. The virus is considered to be a trigger of lymphoma and Kaposi’s sarcoma.

15. Reservoir for HIV viruses elucidated: AIDS patients often suffer from neurological diseases. Scientists of the Institute of Virology were able to show that the HIV viruses not only proliferate in the astrocytes of the brain but also in neural precursor cells.

1. Junior research group investigates insulin resistance: In the Institute of Experimental Ge-netics the new junior research group »Insulin Resistance in Type 2 Diabetes« begins work.

28. The campus celebrates: Together with Bavaria’s Minister President Dr. Günther Beck-stein and Helmholtz President Professor Jürgen Mlynek, more than 700 guests celebrate the re-naming and the new orientation of our center.

Fig. 1

Looking Backat 2008

JANUARY MARCHFEBRUARY

1

1. Adiposity and alcoholism are studied: The Federal Ministry of Education and Research funds etiological research at the molecular le-vel on adiposity, alcoholism and disease-relat-ed signaling pathways.

12. Cornelia Pieper visits the center: The deputy chairman of the Research Committee of the German Parliament discusses research fund-ing and results transfer. Fig. 4

5. Studying in Bavaria: Helmholtz Zentrum München joins Studieren-in-Bayern, an alliance of associations and research institutions.

Fig. 2

28. Total E-Quality in the center: Helmholtz Zentrum München is distinguished for its hu-man resources policy oriented towards equal opportunity for women and men. Fig. 3

7.+8. Program-oriented funding (POF) eval-uated: International experts evaluate the appli-cations of Helmholtz Zentrum München for the second phase of program-oriented funding of the Helmholtz Association of German Research Centres.

LOOKING BACK AT 2008

APRIL JUNEMAY

2

3

4

5

JULY AUGUST SEPTEMBER

1. Diabetes research boosted: The Federal Ministry of Education and Research funds the identification of new metabolite markers within the Competence Network on Diabetes.

19. Research site inspected: Climate change and sustainable soil utilization: Bavaria’s Mi nis-ter President Dr. Günther Beckstein visits Schey-ern Experimental Farm. Fig. 6

1. Department of Zebrafish: The Department of Zebrafish Neurogenetics becomes an inde-pendent research department. Fig. 7

7. HelMA is launched: Leading Alzheimer and Parkinson experts study neurodegenerative dis eases in the Helmholtz Alliance for Mental Health in an Aging Society (HelMA).

15. SAP test phase begins: The new SAP Busi-ness Suite software is tested prior to its launch in 2009.

16. Perspective for Chemical Biology: A sci-entific symposium on Chemical Biology is held at the center.

21.–23. Mathematics for the biosciences: The Institute of Biomathematics and Biometry celebrates its tenth anniversary.

30. From gene to protein: The Proteomics Core Facility in the Genome Analysis Center and the new founded Protein Analytics Depart-ment are launched. Fig. 5

7

9

8

6

JUNIOCTOBER DECEMBERNOVEMBER

18. Information exchange for PhD students: Doctoral Students’ Day provides suggestions for PhD students and their supervisors. Abb. 10

18. Awards for dissertations: Three doctoral students receive the prize of the Association of Friends and Supporters (VdFF) of Helmholtz Zent rum München. Fig. 11

19. Concepts for joint research: The coopera-tion partners of the planned Comprehensive Pneumology Center (CPC) present their re-search proposals.

1. Studies on diseases in old age: KORA-Age studies myocardial infarction, stroke and diabe-tes in Augsburg residents over 65 years.

2. How children stay thin: The Competence Network Adiposity elucidates the scientific ba-sis for the prevention of early obesity in chil-dren.

2. Munich chosen as location for diabetes research: Germany’s Education and Research minister Prof. Dr. Annette Schavan announces the founding of a national diabetes center at Helmholtz Zentrum München.

13.–16. Green chemistry for global prob-lems: Scientists from 22 countries exchange ideas on sustainable concepts in chemistry.

24. Helmholtz Senate approves Helmholtz cohorts. Diabetes, cancer, cardiovascular dis-eases or dementia diseases: 200,000 citizens will be screened for chronic diseases.

5. Board and council approve strategy: The Supervisory Board and the Scientific Council give green light for founding two institutes to research type 2 diabetes.

10. Star tenor for leukemia research: José Carreras visits the clinical cooperation group »Hematopoietic Stem Cell Transplantation« at the University Hospital Munich-Grosshadern.

12.+13. Genome research meets medicine: The research networks NGFN-Plus and NGFN-Transfer position themselves within the grant pro-gram of medical genome research.

17. Munich strengthens allergy research: Tech-nische Universität München and Helmholtz Zent-rum München agree on a joint research center on allergy and the environment.

1. Translational Center for Lung Research is es-tablished: Oliver Eickelberg heads the new pneu-mological research institute as part of the Com-prehensive Pneumology Center (CPC). Fig. 8

5. Germany’s Federal Cabinet decides on Asse transfer: In 2009 the Federal Office of Ra-diation Protection will be responsible for the Asse Mine.

13. Innovative prevention research: The first Helmholtz Forum on Health presents new ap-proaches in preventive research.

15. Alumni form a network: Via the platform www.helmholtz-muenchen.de/alumni former staff members and active staff members can keep in touch and intensify their contacts.

17. Exchange of ideas on Science Day: Staff members report on excellent research results and communicate new concepts that transcend institute borders. Fig. 9

LOOKING BACK AT 2008

10

11

November

Metabolism [Highlights]

We explore the relationships between environmental factors, lifestyle and genetics.

From L to R Stefan Brandmaier (Institute of Bioinformatics and Systems Biology) / Ngia Nguyen (Institute of Soil Ecology) / Fang Wang (Institute of Soil Ecology)) / Ramona Böhm (Comparative Med-icine Department) / Alexander Mannes (Institute of Clinical Molecular Biology and Tumor Ge netics)

The photo was taken on the plaza in front of the Biology Building.

Karsten Suhre Institute of Bioinformatics and Systems Biology

Genetics MeetsMetabolomics

Metabolic diseases such as the increasingly prevalent type 2 diabetes are a consequence of the complex interaction between genetic disposition and unfavorable living conditions. Scientists of Helmholtz Zentrum München and Ludwig-Maximilians-Universität Munich have for the first time shown an association between the genetic makeup of an individual and his/her metabolism.

With the aid of metabolomics the research team was able to capture a detailed ›snapshot‹ of the physiological constitution of the body. For the study the research team combined the genetic data of 284 test subjects with the lab results containing several hundred metabolite values of these test subjects. By comparing the genetic and metabolite data, mutations could be identified for the first time on a genome-wide level, resulting in four genes which are respectively associated with a characteristic trait of the metabolic processes. It is not by chance that these four genes are concerned, as they play a key role for the body’s metabolism. They encode enzymes that are important in particular for the lipid metabolism. In the group of test subjects, individuals had different gene variants and were found respec-tively also to present different characteristic traits in certain metabolic processes, including the synthesis of polyunsaturated fatty acids which play an important role for the cardiovascular sys-tem. From this the scientists could derive genetically determined metabolite patterns. Analogous to the term genotype, which encompasses the genetic features, the metabolite patterns which were identified in the test subjects could be called metabotypes (genetically determined traits of metabolism).

With highly sensitive analytical methods, metab-olomics investigates the small molecules which are present as metabolic products in the body’s cells and tissues.

Genetic makeup determines metabolism: For the first time the association can be shown directly based on metabolic data.

major hetero minor

FADS1

H3C S-CoA

0C20:3

H3C S-CoA

0

C20:4

metabolic rate

rs174548 (FADS1)0 1 2

3,5

3,0

2,5

2,0

1,5

1,0

,5

Tailoring Drugsto Individuals

Research results indicate that metabolomics is the key for tracking the effects of gene mutations. This especially applies when genes are al-tered that encode enzymes and thus play an important role in human metabolism. In the future, metabotypes may help to identify health risks for cer-tain diseases in a much more differentiated way than has been possible until now based on gene analyses – especially for diseases that are closely associated with metabolism. These include common diseases such as diabetes, gout or a narrowing of the coronary vessels which of-ten leads to stroke or myocardial infarction. With knowledge of such metabotypes, patients can be treated in a more targeted manner in the future, because their reactions to drugs and also the influence of nutri-tion and environmental factors can be more precisely assessed against this background. These findings could result in a step towards person-alized health care and nutrition.

HIGHLIGHTS »METABOLISM«

Prof. Dr. Karsten Suhre

Since 2006 Research Group Leader »Metabolomics«, Institute of

Bioinformatics and Systems Biology, Helmholtz Zentrum Mün-

chen, Professor of Bioinformatics at Ludwig-Maximilians-Uni-

versität Munich (LMU)

1994 – 2006 Researcher at Centre National de la Recherche Sci-

entifique (CNRS) in Toulouse and Marseille and in the automo-

bile industry (Karmann 2000 – 2001)

Original Publication:

C. Gieger et al.: Genetics meets metabolomics: a genome-wide

association study of metabolite profiles in human serum. PLoS

Genet. 4 (11):e1000282, 1–12 (2008)

Christa Meisinger, Angela Döring & Christian Gieger Institute of Epidemiology

Genetic Basis for Gout Confirmed

Scientists of Helmholtz Zentrum München have identified variants in the genome which occur in individuals with low uric acid concentrations more frequently than in the normal population. The uric acid level is an important marker for gout. Likewise, it is also frequently associated with oth-er metabolic diseases.

A team of scientists from the Institute of Epidemiology and the Institute of Human Genetics of Helmholtz Zentrum München and from the University of Innsbruck and the University of Greifs-wald have identified a gene involved in the regulation of the uric acid concentration. The research group led by Angela Döring, Dr. Christian Gieger and Dr. Christa Meisinger investigated the asso-ciation between gene variants and uric acid levels in the normal population. Here DNA chips were used which enable the determination of 500,000 of the most frequent variants of the human genome. This genome-wide comparison of frequent variants with uric acid levels – also called a genome-wide association study – was conducted with 1644 individuals from the KORA study (Cooperative Health Research in the Region of Augsburg). The role of the genetic variants could be confirmed in three further independent studies. Since gout runs in families, scientists early on assumed that there was a genetic component in the development of the disease. The studies of the research group show that variants in the SLC2A9 gene are associated with low uric acid levels. The association is stronger in women than in men. Expression studies were able to show that one isoform of the gene explains 15% of the variance of the uric acid concentration in women; in men the effect is less. An elevated uric acid level is the cause of gout and is furthermore associated with cardiovas-cular diseases, diabetes, overweight or the metabolic syndrome. The excess of uric acid in the se-

Gout is a disorder of the purine metabolism in which uric acid crystals are deposited in differ-ent parts of the body, particularly in the area of the joints.

rum can be deposited in the form of small crystals in the joints and soft tissue. This can lead to gout with severe pain attacks and can be observed already at levels between 6 –7 mg/dl. In the Augsburg population 15 % of the 25- to 64-year old men have an uric acid concentra-tion of over 7 mg/dl, while only 1% of women in this age group have uric acid levels that are that high. Generally, pre-menopause women are far less often affected by gout attacks than men. However, after menopause, the incidence increases in women as well. Besides variants in SLC2A9, different causes for an elevated uric acid concentration are known. These include such lifestyle factors as alcohol consumption or high meat consumption as well as diseases or intake of medications which are associated with elevated cell degradation and/or a decreased uric acid excretion in the kidney. In addition, an elevated intake of fructose causes a clear increase in uric acid. What exact role the gene plays in the complex regulation of excretion in the kidney and/or in the production of uric acid in the cell for nucleic acid degradation must now be intensively elucidated in order to understand the cell biological relationships in the de-velopment of hyperuricemia.

Dr. Christa Meisinger

2008 Habilitation, Ludwig-Maximilians-Univ. Munich

Since 2007 Head of the MONICA/KORA Myocardial Infarction Re-

gistry Augsburg

Since 2001 Head of the KORA Study Center Augsburg

2000 Specialist for General Medicine

Angela Döring

1980 – Present Scientific Staff Member, Institute of Epidemiology

1998 – 2008 Lecturer, Ludwig Maximilians -Univ. Munich (LMU)

Dr. Christian Gieger

Since 2009 Research Group Leader »Genetic Epidemiology«

(acting)

Since 2004 Scientific Staff Member, Helmholtz Zentrum München

and Ludwig-Maximilians-Universität Munich (LMU)

1999 – 2004 Worked in industry and at Fraunhofer Institute St.

Augustin


A. Döring et al.: SLC2A9 influences uric acid concentrations with

pronounced sex-specific effects. Nat. Genet. 40(4), 430–436 (2008)


renal arteryrenal veinrenal pelvisureterrenal papillarenal cortexrenal capsule

distal tubulusglomerulusproximal tubulus

glomerulusproximal tubulus

reabsorption 98–100%

reabsorptionsecretionca. 40%

nephron

kidney nephron

100% 0–2% 50% ca. 10%excretion

?

?

Marcus ConradInstitute of Clinical Molecular Biology and Tumor Genetics

How Stress Makes Cells Age

Scientists at Helmholtz Zentrum München have deciphered the molecular mechanisms that trigger cell death in response to oxidative stress. These insights unveiled new targets for intervention in the aging process and in the treatment of degenerative diseases.

The fact that oxidative stress is a major inducer of cell death is a well-accepted current model. Until now, however, the source and nature of reactive oxygen species (ROS) and questions concerning the way they act in cell death signaling have remained obscure. To find answers to these questions, the research group led by Marcus Conrad at the Institute of Clinical Molecular Biology and Tumor Genetics set out to elucidate the molecular function of the prevailing cellular reducing agent, glu-tathione, in the metabolic pathway of cell death. Therefore, the researchers generated mice and cells that specifically lacked glutathione perox-idase 4 (GPx4) – GPx4 is emerging as one of the most important glutathione-dependent enzymes in mammals. The inducible inactivation of GPx4 caused massive oxidation of lipids and cell death.Pharmacological and genetic analyses revealed that lipid peroxides in GPx4-depleted cells do not appear by accidennt but accumulate due to the uncontrolled activation of a specific enzyme of the polyunsaturated fatty acid metabolism, 12/15-lipoxygenase. Activation of apoptosis-inducing-fac-tor (AIF), evidenced by its relocation from mitochondria to the cell nucleus, was identified as an-other important downstream event in this signaling cascade. So far, it was believed that oxidative stress causes a nonspecific oxidation of many essential cellular biomolecules such as proteins and lipids. Contrary to general expectations, however, the researchers found that apparently through the lack of glutathione or GPx4, a distinctive signaling pathway is engaged which sparks cell death.

If the equilibrium in the organism moves towards oxidative processes, this is known as oxidative stress. Among other things, oxidative stress has been associated with the aging of body cells.

Signaling cascade which triggers cell death in case of oxidative stress cell death

AIF

AIFlipid peroxidation

GPx4

GSH

GSH

GSSG

ROS

GSH

2GSH

GSH

12/15-LOX PD146176

siRNA

α-tocopherol

PLA2

COOH

CH3

COOH

CH3

OOH

Slowing AgingProcessesThe data represent the first molecular analysis of a redox-regulated sig-naling pathway, describing how oxidative stress is specifically recog-nized in the body and eventually triggers cell death. Since this cell death cascade can be interrupted by drugs at each in-dividual step, these findings provide novel cues for the targeted treat-ment of many oxidative stress-related human diseases. Acute and chronic degenerative diseases such as stroke, arterioscle-rosis, diabetes, Alzheimer’s and Parkinson’s diseases have been linked to high levels of oxygen radicals. Hence, low cellular concentrations of glu-tathione due to acute or chronic cellular stress may induce the activation of this cell death signaling pathway.

Dr. Marcus Conrad

Since 2005 Research Group Leader, Institute of Clinical Molecu-

lar Biology and Tumor Genetics

Until 2005 Project Leader, Department of Comparative Medicine

Until 2004 Junior Researcher, Helmholtz Zentrum München

2001 PhD, Ludwig-Maximilians-Universität Munich


A. Seiler et al.: Glutathione peroxidase 4 senses and translates

oxidative stress into 12/15-lipoxygenase dependent- and AIF-

mediated cell death. Cell Metab. 8 (3), 237–248 (2008)


Respiratory System [Highlights]

We investigate gene-environment interactions and their importance for breathing.

From L to R Teresa Neumaier (Institute of Radiation Protection) / Christine Moll (Comparative Medi-cine Department) / Andrea Braun (Clinical Cooperation Group »Environmental Dermatology and Aller-gology«) The photo was taken in the free space between the cafeteria and the computer center.

Thomas IlligInstitute of Epidemiology

Stephan WeidingerClinical Cooperation Group Environmental Dermatology and Allergologyand Department of Dermatology and Allergy, Technische Universität München

Key Gene for Allergic Diseases

Scientists of Helmholtz Zentrum München and the Department of Dermatology and Allergology of Technische Universität München have discovered a gene that is important for the development of allergies. The FCER1A gene was discovered at Helmholtz Zentrum München by using state-of-the-art technology with which the entire human genome can be searched.

Why some people are insensitive to allergens during their whole life and others suffer from aller-gies has not yet been fully elucidated. It is known, however, that genetic factors play a crucial role in the development of allergies. Persons with allergies generally have a higher proportion of anti-bodies of the class IgE than healthy individuals. These IgE antibodies are usually important for the defense against parasites, but in allergic individuals they are directed against environmental sub-stances such as house dust mites and pollen, which for most people are harmless. The antibodies are bound via specific IgE receptors to specific cells, preferably in the skin or mucous membranes. Through the coupling to membrane-bound IgE receptors, the IgE production is intensified. Upon contact with the allergen, substances are released from the cells, leading to the known allergic symptoms such as allergic rhinitis (hay fever), atopic dermatitis (neurodermitis) or asthma. The newly discovered FCER1A gene contains the blueprint for the alpha chain of the high-af-finity IgE receptor, which plays a key role in the development of allergy. The alpha chain of this receptor is the binding site for immunoglobulin E (IgE) antibodies. The research team led by Dr. Stephan Weidinger, Technische Universität München, and Dr. Thomas Illig, Institute of Epidemiol-ogy, discovered that certain variants of the identified gene decisively influence the production of IgE and thus the course of the allergy. The study is based on investigations on the genome of more than 10.000 adults and children throughout Germany.

Immunoglobulins (antibodies) are proteins that mark exogenous agents as invasive pathogens and thus make them »visible« for the immune system. Defense cells recognize the marked in-vaders and render them harmless. Different classes (isotypes) of immunoglobulins are pres-ent in different compartments of the body and have different tasks. Antibodies of the class IgE mediate protection against parasites, for example worms, but they can also direct them-selves against per se harmless environmental allergens and thus lead to allergies.

Most of the test subjects of the study originate from the population studies of the KORA research platform (Cooperative Health Research in the Region of Augsburg), headed by Prof. Dr. Dr. H.-Erich Wichmann, director of the Institutes of Epidemiology at Helmholtz Zentrum München and at Lud-wig-Maximilians-Universität Munich. The allergological and dermatological examinations were performed in cooperation with the Department of Dermatology and Allergy of Technische Univer-sität München under the supervision of Prof. Dr. Dr. Johannes Ring. The new findings on the regulation of IgE antibody production allow deeper insights into the mechanisms of the development of allergies and open up new therapy options. Since autoim-mune diseases are likewise associated with IgE antibodies, these findings will not only benefit persons with allergy.

Dr. Thomas Illig

Since 2001 Research Group Leader »Biobanks and Genetic Epi-

demiology of Complex Diseases«


Until 2001: Postdoc at Helmholtz Zentrum München

1995 and 1996: PhD, Postdoc at the University of Regensburg

Dr. Stephan Weidinger

Since 2007 Research Group Leader »Genetics of Allergic Diseas-

es«, Center for Allergy and Environment Munich (ZAUM), Tech-

nische Universität München

2007 Habilitation, Technische Universität München

Since 2005 Specialist in Dermatology and Venerology

1999 PhD, afterwards Clinician in the Clinic and Polyclinic for

Dermatology and Allergology, Technische Universität München


S. Weidinger et al.: Genome-wide scan on total serum IgE levels

identifies FCER1A as novel susceptibility locus. PLoS Genet. 4(8):

e1000166, 1– 9 (2008)

The IgE receptor on antigen-presenting cells consists of one al-pha, one beta and two gamma chains. The alpha chain binds IgE, while beta and gamma subunits are important for signal trans-duction. Certain variants of the gene that encode for the alpha chain (FCER1A) influence the IgE level in blood serum, which it-self is associated with allergic diseases.

α-chain

-chainγ2

C 4 C 3 C 2C 4 C 3 C 2

C 1

C 1

S S

C 4C 3

C 2C 4

C 3C 2

C 1

C 1

S S S S

HIGHLIGHTS »RESPIRATORY SYSTEM«

Joachim HeinrichInstitute of Epidemiology

Allergic to Traffic

Allergic diseases are more common in children who live near busy roads. This is the result of a study led by Helmholtz Zentrum München of several thousand Munich children. The authors eval-uate the results of their study as clear evidence of the adverse effects of traffic-related air pollut-ants on the development of allergies and other atopic diseases.

In a longitudinal study lasting six years, the German research group investigated whether there was a correlation between the level of traffic-related air pollutants and the incidence of atopic diseases. The scientists based their analysis on the respective distance of the parental home to roads busy with traffic as well as on computer-modeled values of the concentrations of fine dust, diesel soot and nitrogen dioxide with respect to the residential address of the children. The research team led by Dr. Joachim Heinrich and Prof. Dr. Dr. H.-Erich Wichmann, Institute of Epidemiology of Helmholtz Zentrum München and Institute of Epidemiology of Ludwig-Maxi-milians-Universität Munich compared the data of approximately 3000 six-year-old children from Munich and surroundings. In two German birth cohort studies (GINI and LISA) the development of these children is being tracked from birth to age six. The studies are coordinated by Helmholtz Zentrum München with the goal of identifying behavioral and environmental risk factors for al-lergic diseases. The results of medical examinations and regular parental questionnaires were included in the current analysis. Furthermore, at age six the children were tested for the presence of specific IgE antibodies against common allergens in blood serum. Using computer models, Verena Morgenstern, doctoral candidate at Helmholtz Zentrum Mün-chen, determined the concentrations of fine dust, diesel soot and nitrogen dioxide for the residen-tial addresses of the children. The results showed that with increasing fine dust exposure, the in-

The adverse effects of traffic-related air pollu-tion on the development of allergies and atopic diseases are known from laboratory tests and inhalation tests. Until now, however, epidemi-ological studies on this subject have failed to supply a clear picture.

Distance to the nearest busy road < 50 metersDistance to the nearest busy road 50 to 250 metersDistance to the nearest busy road 250 to 1000 metersDistance to the nearest busy road > 1000 meters

The odds ratios show that the closer the parental home is to a busy road, the higher the incidence of asthma and allergic sensitization in children.

cidence of asthma and allergic sensitization to pollen and other common allergens in the outdoor air increased. Moreover, elevated nitrogen dioxide exposure was linked to an increase in the incidence of eczema. There were clear associations between the residential environment and the incidence of asthma, hay fever, eczema and allergic sensitization: Children who lived less than 50 meters from a road busy with traffic had an up to 50% higher risk for these diseases than children who lived in areas with less traffic. The statistical analysis of the data showed an increasing risk, the closer the children lived to roads busy with traffic.

Dr. Joachim Heinrich

Since 1997 Deputy Director of the Institute of Epidemiology

Since 1992 Research Group Leader »Environmental Epidemiology«

1990 –1992 Epidemiologist at the University of Wuppertal

1974 –1989 Scientific Assistant and Research Group Leader »Bio-

statistics« at Erfurt Medical School, Graduate Studies and PhD


V. Morgenstern et al.: Atopic diseases, allergic sensitization, and

exposure to traffic-related air pollution in children. Am. J. Respir.

Crit. Care Med. 177 (12),1331-7 (2008)

HIGHLIGHTS »RESPIRATORY SYSTEM«

odds ratio(odds ratio, 95% confidence interval)

asthma sensitization to inhalent allergens

hay fever outdoor allergens

eczema indoor allergens

asthma symptoms

hay fever symptoms

skin symptoms

2.5

2.2

1.9

1.6

1.3

1.0

0.7

2.5

2.2

1.9

1.6

1.3

1.0

0.7

Immune System [Highlights]

We elucidate reactions to endogenous and environmental factors.

From L to R Wei-Yen Liao (Institute of Stem Cell Research) / Andrea Braun (Clinical Cooperation Group »Environmental Dermatology and Allergology«) / Philipp Hoppe (Institute of Stem Cell Research)

The photo was taken in the rock garden between the Genetics Building and the Biologikum.

Dirk H. BuschClinical Cooperation Group »Antigen-Specific Immunotherapy« and Institute of Microbiology, Immunology and Hygiene, Technische Uni-versität München

Protection Against Infections: What a Single Cell Can Do

Researchers of the Clinical Cooperation Group »Antigen-Specific Immunotherapy« have shown that different cell types can evolve from a specialized T cell. Until now only stem cells were known to have this broad range of development potential.

The aim of the research group is to isolate defined T cells using biotechnological methods so that they can be utilized in treatment of tumor diseases and infections. From patient studies it is known that vaccination with T cells bearing a pathogen-specific receptor can provide effective protection against infection. However, immune cells cultivated in the lab did not turn out to be very effective after transfer to the recipient. Busch and his colleagues vaccinated mice with only one single pathogen-specific T cell. This T cell was ›specialized‹ to respond to listeria – bacteria that are the cause of the infectious disease listeriosis. Single T cells were extracted from animals that had survived an infection with the bac-teria. The research team tracked the path of the single immune cells throughout the bodies of the recipient mice and could observe that first of all, the progeny of a single listeria-specific T cell formed effector cells in the spleen and lymph nodes. Later, the researchers detected the presence of immune memory cells in the spleen, lymph nodes and the lung. The reason why protection against listeriosis could be transferred to mice by single T cells is that the transferred cell generat-ed a number of different T-cell types. Among them are cells that are responsible for the immediate immune response, as well as long-living memory cells, which ›memorize‹ the specific immune re-sponse they have once learned. By contrast, in the transfer of cultivated T cells much larger quan-tities of cells were needed, and the immunization effect was significantly weaker.

After bone marrow transplantation it can take quite a long time for a new immune system to build up protective T cells. During this time in-fections that are per se harmless can be life-threatening for transplant patients.

A single immune cell is able to put up a ›defense shield‹ against a specific pathogen: The cell divides and generates different immune cell types – short-lived effector cells (SLEC), long-lived central memory T cells (TCM) and effec-tor memory T cells (TEM) – for the different organs and tissues.

stem cell-like plasticity

naive

TE

TEM

TCM

activation maintenanceexpansion

»memory« stem cell

continuous influencing

Boosting theImmune SystemThe targeted cell transfer was made possible through an approach called MHC Streptamer, which was also developed by Dirk H. Busch and his team. With this technology individual T cells can be isolated from blood samples – faster and more cost-effectively than with previous methods. Currently this cell transfer is being tested in three clinical trials. First pa-tients that had been treated with a stem cell transplantation and subse-quently suffered from Cytomegalovirus (CMV) infection were immunized with merely a few thousand CMV-specific cells of the stem cell donor. Al-ready after a short time they showed an effective immune reaction. This kind of immunotherapy using the novel cell isolation method appears to be a very promising treatment approach: After the transfer, donor cells trigger a more effective immune response than immune cells which have been harvested from cell cultures. Moreover, dangerous ad-verse side effects are avoided, because with this method T cells can be harvested in highest purified form. Undesirable T cells could trigger an immune reaction against the foreign organism. However, this does not occur because only the selected pathogen-specific T cells are transferred to the transplant recipients.

Prof. Dr. Dirk H. Busch

Head of the Clinical Cooperation Group »Antigen-Specific Immu-

notherapy«

Since 2009 Director of the Institute of Microbiology, Immunology

and Hygiene, Technische Universität München

Since 2004 C3 Professor at Technische Universität München,

previously scientific staff member

Until 1999 PhD and postdoc, development of new methods to

isolate T cells at Yale University


C. Stemberger et al.: A single naive CD8+ T cell precursor can

develop into diverse effector and memory subsets. Immunity 27

(6), 985 – 997 (2007)

HIGHLIGHTS »IMMUNE SYSTEM«

Arnd KieserGene Vectors Department

Tricky Tumor Viruses

Scientists of the Gene Vectors Department were able to show that Epstein-Barr virus alters the properties of a signaling protein of their host cells. The research group led by Dr. Arnd Kieser has succeeded in elucidating a key mechanism of tumor induction by the Epstein-Barr virus.

Viruses use many tricks to gain control over their host cells and to reprogram them to their own advantage. Dr. Arnd Kieser and his colleagues were able to show that Epstein-Barr virus mediates cell proliferation by exploiting a signaling protein of its host cell that usually mediates apoptosis.Epstein-Barr virus (EBV) is a human-pathogenic virus which belongs to the herpes virus family. Its viral genome consists of double-stranded DNA, and it is one of the few known viruses which cause cancer in humans under certain circumstances. EBV-associated cancers include lymphomas (can-cer of the lymph nodes), nasopharyngeal carcinoma and gastric cancer. A protein encoded by the virus, the latent membrane protein 1 (LMP1), is required for the un-controlled proliferation of EBV-infected cells and thus the development of cancer. Arnd Kieser and his team are studying the molecular mechanism of action of this EBV protein. LMP1 is a membrane-bound oncoprotein that binds certain signaling molecules of its host cell and thereby critically contributes to the oncogenic transformation of the cells. One of these signal proteins is the factor TRADD. TRADD stands for TNF-receptor 1-associated death domain protein. The scientists used TRADD knockout cell lines which they had established by removing both alleles of the gene from the genome of human B cells in order to demonstrate that TRADD is an essential factor for LMP1 function: In the absence of TRADD, LMP1 can no longer activate NF-κB, a signal transduction pathway which is crucial for cell transformation. Usually, TRADD also induces pro-grammed cell death which is also called apoptosis. Induction of cell death, however, would be

Almost every adult is a carrier of Epstein-Barr virus (EBV), which belongs to the family of her-pes viruses. With an infestation rate of more than 90%, EBV is one of the most successful human viruses.

counterproductive for the virus, because it would be adversely affected by the death of its host cell. In fact, the scientists made the surprising observation that TRADD activated by the viral protein LMP1 no longer induces apoptosis. But how does Epstein-Barr virus manage to specifically switch off the apoptosis function of TRADD? Kieser and his colleagues discovered that the LMP1 protein possesses a unique TRADD binding domain, which recruits the cellular TRADD protein and alters its molecular properties so that the apoptosis signals can no longer be transmitted. – Thus, LMP1 masks the apoptosis activity of TRADD. This viral TRADD-binding domain consists of the 16 carboxyterminal amino acids of the LMP1 protein and can be transferred to cellular receptor proteins where it shows the same effects.Hence, Epstein-Barr virus has found a unique molecular way to extinguish an undesired property of a cellular protein in order to adapt this protein to its own needs. This finding might also be the basis for a new therapeutic approach. The scientists surmise that since the specific structure of the LMP1-TRADD interaction is most likely restricted to EBV-infected cells, it might serve as a target structure to develop specific inhibitors which interrupt the transforming signaling cascade of the LMP1 oncogene.

Dr. Arnd Kieser

2008 Habilitation in Genetics, Technische Universität München

Since 2001 Research Group Leader »Signal Transduction«

1996 –2000 Postdoc and Junior Research Group Leader, Insti-

tute of Clinical Molecular Biology and Tumor Genetics

1993 –1996 Graduate Studies and PhD, National Cancer Insti-

tute, Bethesda, Maryland, Helmholtz Zentrum München and

Ludwig-Maximilians-Universität Munich


F. Schneider et al.: The viral oncoprotein LMP1 exploits TRADD

for signaling by masking its apoptotic activity. PLoS Biol. 6(1):

e8, 1–13 (2008)

.


Epstein-Barr virus encodes the oncoprotein LMP1, which binds signaling molecules of the host cell. When LMP1 activates the signaling protein TRADD, the anti-apoptotic NF-κB pathway is induced and the apoptosis program of the cell is suppressed: The virus-transformed host cell can proliferate further.

LMP1

NF-κB-signaling p athway

LTB

CTAR1

371

TRADDJNK signaling pathway

recruiting

activationBS69

IKK

TRAF6

apoptosis

Helmut Fuchs & Martin Hrabé de AngelisInstitute of Experimental Genetics, Helmholtz Zentrum München and Technische Universität München

The Guardian of the Genome and the Protein Factories of the Cell

The molecule p53 is called the »guardian of the genome« because it can suppress cells that are proliferating uncontrollably and can thus inhibit cancer cell growth. However, the molecule p53 also reacts to certain defects in the protein factories of the cell, the ribosomes. It can then cause various disorders in humans and animals, as scientists at Helmholtz Zentrum München collabo-rating in an international study with colleagues from Stanford University and the University of Michigan were able to demonstrate.

How do light-skinned mice get dark paws, tails and ears? Mutations in the DNA of the mice are responsible for the abnormal pigmentation. However, as the study in the Munich ENU Mutagen-esis Project shows, these mutations that were identified by Dr. Helmut Fuchs affect far more than the color of the skin and hair of the mice. The international research team was able to show that two of the genetic mutations impair components of the ribosomes to such an extent that the cel-lular protein factories cannot or cannot adequately fulfill their functions. It is already known that defects in certain ribosomal subunits can have a number of conse-quences. On the one hand, the formation of ribosomes from several components is more difficult, which then affects the production of proteins adversely. Moreover, the lifespan of the affected cells is shortened. Genetically caused defects in ribosomes can also lead to serious disorders such as Diamond-Blackfan anemia in humans. Patients with this innate bone marrow disease do not produce sufficient red blood cells, are delayed in their growth and can develop cranial deforma-tions, among others. Last not least, the mice with the black paws substantiate this association to ribosomal de-fects: Closer analysis showed that the animals also suffered from anemia with similar effects as

Ribosomes are structures in the cell nucleus in which proteins are produced.

Dr. Helmut Fuchs

Since 2001 Scientific and Technical Head of the German Mouse

Clinic

Since 1997 Scientist at Helmholtz Zentrum München

Until 1997 Graduate Studies and PhD, Technische Universität

München

Prof. Dr. Martin Hrabé de Angelis

Since 2000/2003 Director and Chair, Institute of Experimental

Genetics, Helmholtz Zentrum München and Technische Universi-

tät München

Since 2000 Director, German Mouse Clinic and European Mouse

Mutant Archive

1997– 2000 Research Group Leader »Functional Genetics«

1994 –1997 Postdoc, Jackson Laboratory Maine, USA

1990 –1994 Graduate Studies and PhD, Philipps University Mar-

burg and Max Planck Institute, Freiburg


K.A. McGowan et al.: Ribosomal mutations cause p53-mediated

dark skin and pleiotropic effects. Nat. Genet. 40 (8), 963 – 970

(2008)

with the Diamond-Blackfan syndrome. The research team was able to prove that the diseases caused by defective ribosomal proteins have a common molecular origin. And this mechanism leads to an accumulation of p53. The p53 molecule is one of the most important factors in the body’s fight against excessive cell growth and the development of cancer. As so-called tumor suppressor gene, p53 can initiate various countermeasures when a cell divides uncontrollably – and ultimately it can even trigger their apoptosis. The paramount importance of this molecule is also illustrated by the fact that p53 is defective in circa half of all human tumors. But the »guardian of the genome« also has its dark sides and can even cause diseases. This undesirable effect of p53 can evoke different symptoms. The respective effect depends in which cell type the tumor suppressor gene is activated. This also means that p53 serves as a kind of sen-sor to determine the functional ability of ribosomes. If they are defective it can trigger various symptoms depending on the cell type and kind of tissue.In Diamond-Blackfan anemia this may occur via apoptosis of the cells in the bone marrow which produce blood cells. The new findings on the role of p53 in these disorders may lead to improved diagnosis and treatment of severe anemias.


Diseases caused by defective ribosomal proteins express them-selves in very different ways. One reason is thought to be the defective activation of the guardian molecule p53.

Rp/Rp

reduced growth and diminished body

Kitl apoptosis

melanocyte proliferation anddark skin

hypoplasia of erythrocytes and anemia

activation of p53

Helmut Fuchs & Martin Hrabé de AngelisInstitute of Experimental Genetics, Helmholtz Zentrum München and Technische Universität München

Nervous System [Highlights]

We study multifactorial diseases.

From L to R Anna-Lena Marwedel (Institute of Developmental Genetics) / Ramona Zeh (Institute of Experimental Genetics) / Franziska Knauf (Institute of Human Genetics)

The photo was taken on the inside balcony of the computer center.

Juliane Winkelmann & Thomas MeitingerInstitutes of Human Genetics, Helmholtz Zentrum München and Technische Universität München

New Risk Gene Discovered for Restless Legs Syndrome

An international research team has succeeded in identifying PTPRD, a protein tyrosine phosphatase, as risk gene for RLS. Altogether, now four RLS genes have been discovered through genome-wide genetic studies. Carriers of risk sequence variants in these genes have a heightened risk of contract-ing RLS: Due to the known functions of the identified genes, RLS could be an early developmental disorder of the central nervous system.

Although RLS is one of the most common neurological disorders, it is still often not recognized or is falsely diagnosed. The Institutes of Human Genetics at Helmholtz Zentrum München and at Technis-che Universität München as well as at the Max Planck Institute of Psychiatry have been working for many years to expand knowledge about the underlying mechanism of RLS and to create an im-proved basis for diagnosis and therapy of the disease. Together with an international consortium, the Munich scientists studied a total of 2458 RLS patients and 4749 healthy test persons of the KORA population study. Sequence variants (SNPs) were analyzed that were distributed over the whole genome. Upon comparison of the sequences between the patients and the control persons, variants in the PTPRD gene could be identified that are present in increased numbers in RLS patients, but appear less of-ten in healthy test persons. The gene name PTPRD stands for protein tyrosine phosphatase receptor type delta. The corre-sponding protein has been studied in the animal model and plays a role in the correct pathfinding of the neuron axons to the so-called motor neurons. These neurons regulate muscles directly or indi-rectly, for instance in the legs. Hence, PTPRD, just as the already identified RLS risk genes MEIS1, BTBD9 and LBXCOR1, is important for the early embryonic development of the organism. This is

Restless Legs Syndrome (RLS) is a neurological disease characterized by unpleasant sensations in the legs at night. Patients suffer from a strong urge to move, making restful sleep impossible.

Results of the genome-wide association study for the PTPRD gene and surround-ing region on chromosome 9.

a further indication that RLS could be a very early developmental disorder of the central nervous system. The identified RLS risk genes enable for the first time targeted molecular genetic causal research of Restless Legs Syndrome and provide a basis for improving therapy.

Dr. Juliane Winkelmann

Since 2008 Senior Physician, Neurological Clinic and Institute of

Human Genetics, Technische Universität München

2005 – 2008 Research Group Leader, Institute of Human Genetics,

Helm holtz Zentrum München & Max Planck Institute of Psychiatry


Prof. Dr. Thomas Meitinger

Since 2000 Director, Institute of Human Genetics, Helmholtz Zent-

rum München and Technische Universität München

Until 2000 Head of the Laboratory of Molecular Genetics, Chil-

dren’s Hospital of Ludwig-Maximilians-Universität Munich

Until 1988 German Research Foundation scholarship holder at

the University of Oxford

Until 1985 Assistant, Dept. of Pediatric Surgery, Municipal Hos-

pital Karlsruhe

Until 1983 Graduate studies and PhD, scientific and practical

work at the universities in Munich and in Johannesburg


B. Schormair et al.: PTPRD (protein tyrosine phosphatase recep-

tor type delta) is associated with restless legs syndrome. Nat.

Genet. 40 (8), 946 – 948 (2008)

HIGHLIGHTS »NERVOUS SYSTEM«

-log10(pnom)

genome position (base pairs)

rs1975197

rs4626664

rs4741557

500,000 5,500,000 10,500,000 15,500,000 20,500,000 25,500,000 30,500,000

4

3

2

1

0

Magdalena GötzInstitute of Stem Cell Research and Physiological Institute of Ludwig-Maximilians-Universität Munich

Neurons from Glial Cells

Scientists of the research group of Prof. Dr. Magdalena Götz at Helmholtz Zentrum München and at Ludwig-Maximilians-Universität Munich discovered that reactive glial cells in the mouse brain can resume cell division following injury. These reactive glia cells become stem cells out of which, under favorable conditions in cell culture, neurons can form again. With this new discovery, the research group has thus succeeded in elucidating a further step to understanding the processes which can replace damaged brain cells after injury.

The scientists were able to show that normal star-shaped glial cells, the astrocytes, have the ca-pacity to differentiate into neural stem cells following injury. They begin dividing again in the in-jured brain and even have typical stem cell characteristics. Although the astrocytes in the injured region of the brain only form new astrocytes, some of them under favorable conditions in cell culture can renew themselves and form neurons, oligodendrocytes and astrocytes – all main cell types of the central nervous system. In their research the scientists could only observe the formation of new nerve cells in cell culture. Even if adult neural stem cells are transplanted into the brain, most of them only form glial cells. This means that there are strong in vivo signals from the surroundings that inhibit the formation of neurons in the adult brain. However, the research group led by Magdalena Götz was able to show that by introducing particularly strong signal molecules, cells can be stimulated to form neurons again – even locally in the injured region of the brain. Magdalena Götz, the stem cell expert, is investigating the molecular basis of brain development, especially in the cerebral cortex, and the mechanisms of the formation of neurons in the adult brain.

Glial cells comprise a large part of the brain mass in the human brain. The star-shaped as-trocytes are an important type of glia cell which not only regulate the metabolic processes in the brain, but also have neural stem cell char-acteristics. The oligodendrocytes isolate nerve fibers conducting neuronal signal transduction.

In injured regions of the brain glial cells start dividing again. Some of these cells can gener-ate neurons, oligodendrocytes and astrocytes.

oligodendrocyte

neuron

astrocyte

Regenerating Brain CellsThe research of Magdalena Götz casts doubt on one doctrine of neurobi-ology, namely the pure ›support‹ role of glia. In earlier studies, Magdale-na Götz discovered that glial cells in the brain can function as stem cells and that neurons are generated from these glial cells. She also showed which factors play a role in the cross-over from glial cells to neurons. The findings open up new avenues towards highly innovative therapeu-tic approaches by utilizing the endogenous glia for repair of degenerat-ing neurons in the brain. In 2007 Magdalena Götz received the Gottfried Wilhelm Leibniz Prize, the highest scientific honor in Germany, for her research achievements. The new findings provide decisive evidence that in an injured region of the brain, reactive glial cells possessing the potential of stem cells are present and thus can serve as source for new neurons. These results im-ply that the distant goal of being able to use these processes therapeuti-cally is getting a little closer.

Prof. Dr. Magdalena Götz

2007 Gottfried Wilhelm Leibniz Prize of the German Research

Foundation (DFG)

Since 2004 Institute Director at Helmholtz Zentrum München

and Chair of Physiological Institute of Ludwig-Maximilians-Uni-

versität Munich

Until 2003 Scientist and Research Group Leader at Max Planck

Institutes in Göttingen and Munich

Until 1996 Graduate Studies and PhD, Postdoc in Tübingen, Lon-

don and Harlow


A. Buffo et al.: Origin and progeny of reactive gliosis: A source of

multipotent cells in the injured brain. Proc. Natl. Acad. Sci. U.S.A.

105 (9), 3581– 3586 (2008)


Jochen GrawInstitute of Developmental Genetics

Genetic Defect Leads to Clouded Lens

At Helmholtz Zentrum München a genetic defect was deciphered which is responsible in mice for unusually small eyes and an incompletely formed, clouded lens. Conclusions can be drawn from these findings about cataracts in humans, because also in this case the lens body loses its transparency.

The Aey12 mouse mutant, which the research team led by Prof. Dr. Jochen Graw at the Institute of Developmental Genetics discovered, is characterized by unusually small eyes, a microphthalmia. This malformation is also known in humans and almost always leads to blindness. It is often caused by atrophy or malformation of the eyeball. In the Aey12 mice, by contrast, the growth of the fibers that fill in the lens body are blocked. What remains is a cloudy and functionless lens vesicle. As the scientists were able to show, the disease is caused by a defect in a gene that was previ-ously unknown. The Neuherberg eye researchers gave the name Gjf1 to this gene responsible for the malformations of the Aey12 mouse mutants. It is a member of the connexin family. The genes belonging to this group contain the blueprint for the channel proteins, which form cell to cell con-nections. Such channels are of great importance for the exchange of substances between cells – including the exchange between the fiber cells of the developing ocular lens. The scientists now speculate that through the newly discovered mutation, the structure of the Gjf1 channel protein is changed, and in this way the formation of the channel is hindered. Through this, however, the communication between the developing lens fibers would break down. As a consequence, signal molecules essential for the development of the lens could no longer be ex-changed, or could only be exchanged to a limited extent. In this scenario, deficient cell communi-cation would be the cause of the termination of fiber development – and ultimately, of the cloudi-ness of the eye lens, which would otherwise be transparent. This same phenomenon can also be

The ocular lens, which in the healthy eye is elas-tic and transparent, focuses light beams falling on the retina. Disorders in the differentiation of the lens fiber cells are involved in the develop-ment of cataracts, which often appear in the el-derly.

In a very early phase in embryonic development the primary fi-ber cells grow into the lens vesicle and thus form the lens body. Genetically caused disturbances in the exchange of signals be-tween the fiber cells lead to termination of the lens development.

observed in human cataracts, a disease common in old age. In Germany alone more than half a million operations are carried out annually in which the cloudy and opaque lens is replaced with an implant. From these findings on the genetic development of the ocular lens of the mouse, the research-ers hope to better understand comparable genetic mutations in humans and to gain new insights into the origin of cataracts.

Prof. Dr. Jochen Graw

Since 1999 Professor, Technische Universität München

Since 1992 Research Group Leader »Molecular Eye Development«,

Institute of Developmental Genetics

1991 Habilitation in Genetics

Since 1981 Scientific Staff Member, Helmholtz Zentrum München

1979 –1981 Graduate Studies and PhD, University of Constance


O. Puk et al.: Mutation in a novel connexin-like gene (Gjf1) in

the mouse affects early lens development and causes a variable

small-eye phenotype. Invest. Ophthalmol. Vis. Sci. 49 (4), 1525

–1532 (2008)


lens epitheliumlens fiber cellvitreous bodyretinaoptic nerve

ophthalmic cup shaftprimary lens fiber celllens capsulelens vesiclelater cornea

From L to R Anna-Lena Idzko (Institute of Radiation Protection) / Angelique Ale (Institute of Biological and Medical Imaging) / Thomas Jetzfellner (Institute of Biological and Medical Imaging) / Claudia Mayerhofer (Institute of Biologi-cal and Medical Imaging) / Saskia Björn (Institute of Biological and Medical Imaging) The photo was taken on the Garching Heath north of the research campus of Helmholtz Zentrum München.

Focus Spanning [Highlights]

We are trying to find answers to the urgent problems of society.

Karl-Heinz LadwigInstitute of Epidemiology

Fight Against Memories

Up to 20% of heart attack patients are affected by post heart attack depression. They have a sig-nificantly higher mortality rate than patients who do not suffer from stress, if the stress disorder is not treated. This is the result of a study on approximately 150 patients that had received an automatic cardioverter defibrillator (ICD) after a heart attack or cardiac arrest.

A team of scientists from Helmholtz Zentrum München, Technische Universität München and the German Heart Center showed that heart attack patients with posttraumatic stress disorder have a 3.5-fold higher mortality risk than patients without this diagnosis. In the study led by Prof. Karl-Heinz Ladwig the scientists observed 147 patients over a period of five years. They had survived a severe heart attack or sudden cardiac arrest, and they had received a pacemaker-sized automatic cardioverter defibrillator (ICD) implanted to prevent another cardiac arrest. The scientists asked detailed questions about symptoms which typically occur in posttraumatic stress disorder: anx-ious, intrusive memories of the life-threatening event, avoidance of behavior reminding them of the event as well as heightened nervous agitation or hypervigilance after the primary event. A portion of the patients had elevated PTSD symptoms, and their lives were defined by recur-ring intrusive memories of their illness. They lived in a permanent state of anxiety and tenseness. These individuals exhibited a 3.5-fold higher mortality risk than patients who did not suffer from these symptoms and who were able to cope with their illness. How dramatic the survival gap ac-tually is between cardiac patients with and without PTSD symptoms was also evident in the anal-ysis of the absolute risks: Compared with 55 fatal events per 1000 person-years in patients with-out PTSD, the long-term absolute mortality risk accounted for 80 fatal events per 1000 person-years in patients with PTSD.

A posttraumatic stress disorder (PTSD) is trig-gered by an exceptionally threatening or cata-strophic event and can have severe emotional and physical consequences.

Other important factors influencing patients’ ability to survive after a heart attack were not asso-ciated with the risk of posttraumatic stress symptoms. Such risk factors include age, the ejection fraction as measure of the remaining myocardial contractility, or diabetes mellitus. Surprisingly, the researchers found no association with the presence of co-morbid depression and anxiety. The scientists concluded that the risk of PTSD is independent of the other above-named risk factors and cannot be explained by them. The study is a contribution to improve cardiac patient care and long-term outcome. It shows that more attention should be dedicated to cardiac patients who exhibit PTSD symptoms to in-crease their survival rate.

Prof. Dr. Karl-Heinz Ladwig

Since 2000 Deputy Research Group Leader »Epidemiology of

Chronic Diseases«, Institute of Epidemiology, Helmholtz Zent-

rum München

Since 2002 Professor of Psychosomatic and Psychological Medi-

cine, Technische Universität München

Since 1998 Head of the psycho-physiological laboratory at the

German Health Center in Munich, Habilitation


K.H. Ladwig et al.: Posttraumatic stress symptoms and predicted

mortality in patients with implantable cardioverter-defibrilla-

tors: results from the prospective living with an implanted car-

dioverter-defibrillator study. Arch. Gen. Psychiatry 65 (11), 1324

–1330 (2008)

FOCUS SPANNING

< 60 years > 60 years

160

140

120

100

80

60

40

20

0

The mortality risk for heart attack patients with posttrau-matic stress disorder (PTSD) is significantly higher than that of patients with less stress. The diagram shows the mortality rates per 1000 person-years broken down accord-ing to age group and degree of the posttraumatic disorder.

minor PTSD PTSD

Vasilis NtziachristosInstitute of Biological and Medical Imaging and Chair of Biological Imaging at Technische Universität München

In Vivo Imaging of the Molecular Signatures of Lung Tumors

Together with colleagues from Harvard Medical School and Massachusetts General Hospital in Boston, USA, Professor Vasilis Ntziachristos and his team have developed a new method capable of optimized fluorescence-tomographic imaging of tumors. Ntziachristos, who heads the Institute of Biological and Medical Imaging at Helmholtz Zentrum München and at Technische Universität München, and his team have developed a method which enables the use of so-called early-arriving photons in tomographic procedures.

Early-arriving photons are the first photons that arrive onto a photon detector after illumination of tissue by an ultra-short photon pulse and undergo less scattering in comparison to photons arriv-ing at later times. Compared to continuous illumination measurements a combination of these less scattered photons with 360-degree illumination-detection resulted in sharper and more accurate images of mice under investigation. With this technique, called early photon tomography (EPT), the scientists imaged lung tumors in living mice. For this purpose they injected a substance into to the animals, which normally does not fluoresce, but becomes fluorescent after contact with certain cysteine proteases such as cathep-sins. The amount of these proteases is enriched in lung tumors, which allows fluorescence imaging of the tumor tissue. Comparison with conventional x-ray tomography showed that EPT is not only a very sensitive technique for imaging of lung tumors in living organisms, but also has the potential to reveal bio-chemical changes in neighboring tissue regions, which are caused by the tumor disease and which cannot be detected by conventional X-ray imaging.

Fluorescent molecules are useful aids in medi-cine and biology in order to track cellular and subcellular function such as gene expression, molecular pathways, protein concentration and function or metabolic processes. In conjunction with powerful new optical tomography tech-niques it offers new ways of looking into ›-om-ics‹ fields through entire organisms in vivo.

Experimental arrangement of the early-arriving photons method: A pulsed laser emits ultra-short photon pulses, which hit the ob-ject of study and are scattered there. A special camera detects on-ly the early-arriving photons to reduce the effects of photon scat-tering and reconstructs images of fluorescent contrast in vivo.

controlled CCD camera

rotation unit

telecentric lens

imaging camera

galvanometer pair

high-frequency imaging device

femto-second laser

Making Disease Processes VisibleThe new technique enables the imaging of tumors in living animals. The method results in sharper and more accurate images than traditional methods. Hence, fluorescent techniques in combination with imaging diagno-sis techniques allow the investigation of disease processes and tissue functions. However, a massive obstacle to the application of the tech-nique in living organisms is the massive scattering of the light in biologi-cal tissue. The German-American research group circumvented this problem by using an ultra-fast pulsed laser. Photons from such a source penetrate tissue and are only slightly scattered. The first photons to reach the de-tector are used for high-resolution imaging. At present EPT is practicable only with small animals. Further development of the equipment can al-low applications of the technique also with larger organisms including humans.

Prof. Dr. Vasilis Ntziachristos

Since 2007 Director of the Institute of Biological and Medical Im-

aging, Helmholtz Zentrum München and Chair of Biological Imag-

ing, Technische Universität München

Until 2007 Assistant Professor, Harvard University Medical School

and Massachusetts General Hospital

2004 Top 100 of the World’s Best Innovators

Until 2001 Postdoc, Harvard University, graduate studies and PhD

at the University of Pennsylvania


M.J. Niedre et al.: Early photon tomography allows fluorescence

detection of lung carcinomas and disease progression in mice in

vivo. Proc. Natl. Acad. Sci. U.S.A. 105 (49), 19126–19131 (2008)

FOCUS SPANNING

Norbert HertkornInstitute of Ecological Chemistry

Nature Follows Mathematics

Scientists of Helmholtz Zentrum München have succeeded for the first time in detecting the maxi-mum possible number of chemical compounds out of carbon, oxygen and hydrogen in natural or-ganic matter. This opens up new insights into the role of this widespread material in the global carbon cycle and thus for the world’s climate.

The maximal conceivable number of different chemical combinations of carbon, oxygen and hydro-gen can be calculated mathematically. Using a new ultra-high-resolution mass spectrometer, sci-entists of the Institute of Ecological Chemistry at Helmholtz Zentrum München in collaboration with the Alfred Wegener Institute Bremerhaven and the Georgia Institute of Technology have suc-ceeded in proving for the first time – not only theoretically but practically – that the maximum possible number of chemical compositions out of carbon, oxygen and hydrogen actually exists in natural organic matter (NOM). Little was known until now about NOM in the environment, but in fact it is present in considerable quantities in nearly all areas of the environment – in soil, sedi-ment, fresh and salt water and in the air. It arises from the decomposition of organic substance and thus forms the link in the chain between the animate and inanimate environment. The new high-resolution analysis technique used at Helmholtz Zentrum München now enables considerably im-proved insight into the structural chemistry of this ubiquitous natural material. As study material the scientists chose a NOM fraction which is recognized and widely used in the scientific commu-nity as standard reference compound, the SuwFA, a fulvic acid fraction from the Suwannee River in the state of Georgia in the U.S. The FTICR mass spectrometer the scientists used was indeed able to detect all conceivable C-H-O compositions in the sample, proving that nature has in fact realized in NOM all mathematically possible chemical combinations.

Dr. Norbert Hertkorn

2006 Habilitation, Technische Universität München

Since1990 Scientist, Helmholtz Zentrum München

Until 1989 Postdoc, University of California Berkeley

Until 1987 Graduate studies and PhD, scientific assistant Tech-

nische Universität München


N. Hertkorn et al.: Natural organic matter and the event horizon

of mass spectrometry. Anal. Chem. 80 (23), 8908 – 8919 (2008)

The abbreviation FTICR stands for Fourier Trans-form Ion Cyclotron Resonance (mass spectrom-eter), which is distinguished by its extreme mass resolution and high mass accuracy.

The gray dots represent the mathematically possible 18,414 combinations of carbon, hydrogen and oxygen molecules. The colored dots mark the variations that have actually been detected in natural organic matter.

oxygen-carbon ratio

hydrogen-carbon ratio

2

1.5

1

0.5

0

0 0.25 0,5 0.75 1

organic contaminants(benzene, toluene)

groundwater flow direction

Tillmann LüdersInstitute of Groundwater Ecology

Hot Spots in Groundwater

Microorganisms degrade contaminants in groundwater preferably in gradient zones around con-taminant plumes. Scientists of the Institute of Groundwater Ecology were now able to detect such degradation hot spots and the highly specialized microbial community established in them in an aquifer contaminated with tar oil.

The research team led by Dr. Tillmann Lüders and Dr. Christian Griebler investigated the spatial distribution of groundwater microorganisms in the contaminant plume underneath a former gas works site near Düsseldorf. Using high-resolution molecular biological and hydrogeochemical methods, they found a community of microorganisms specialized in the degradation of hydrocar-bons in the gradient zone to the contaminant plume. This gradient zone in which tar oil compo-nents and sulfate as important electron acceptor mix harbors a high abundance of a previously unknown anaerobic toluene degrader, which could be identified based on its catabolic genes. This sulfate-reducing gradient zone, the researchers concluded, is a hot spot of microbial con-taminant degradation. The findings show that the distribution of microbial communities and degradation processes in contaminated aquifers are closely linked. They can therefore be used as a starting point for es-timating the natural self-purification potential of groundwater, our most important drinking wa-ter resource.

Dr. Tillmann Lüders

Since 2004 Research Group Leader, »Molecular Ecology«, Insti-

tute of Groundwater Ecology

2002 – 2004 Postdoc, Department of Biogeochemistry, Max Planck

Institute for Terrestrial Microbiology, Marburg

1999 –2001 Graduate Studies and PhD, Max Planck Institute for

Terrestrial Microbiology and the University of Marburg


C. Winderl et al.: Depth-resolved quantification of anaerobic tol-

uene degraders and aquifer microbial community patterns in

distinct redox zones of a tar oil contaminant plume. Appl. Envi-

ron. Microbiol. 74 (3), 792 – 801 (2008)

FOCUS SPANNING

Organic contaminants in groundwater are in-fluenced by a number of biotic and abiotic pro-cesses. The most important purification capaci-ty is contributed by specialized communities of microbial contaminant degraders.

Where does degradation occur?Which microorganisms are responsible?What controls their activity?

Looking AheadWe are pursuing a common scientific goal.

From L to R Saskia Björn (Institute of Biological and Medical Imaging) / Stefan Brandmaier (Institute of Bioinformatics) / Christine Moll (Comparative Medicine Department) The photo was taken in front of the sculpture created by Hermann Bigelmayr in 1992 in the entrance area of Helmholtz Zentrum München.

The three POF programs »Systemic Analysis of Multifactorial Diseases«, »Environmental Health« and »Terrestrial Environment« provide an ex-cellent framework for our research. We are focusing on developing indi-vidualized therapies for widespread diseases – in particular metabolic and respiratory diseases and disorders of the nervous and immune sys-tems. We are striving to elucidate the causes and mechanisms of diabetes mellitus by concentrating the national competence in this field at the Munich location. Beyond the planned federation of German diabetes centers, we will expand our capacity – together with the two Munich universities – by adding two new research institutes and two new clini-cal cooperation groups. Based on the knowledge we have gained, we are endeavoring to make medical advancements in all of our core research areas, and are therefore continuing to expand translational research. Helmholtz Zent-rum München is outstanding in basic research, and we are committed to advancing the ideas derived from it. Projects with potential for commer-cialization are being developed along the value chain for use in new therapeutic and diagnostic applications. For the development of new active pharmaceutical ingredients (API), we need capabilities in the fields of chemistry and assay development at the Center. This is why we have launched an initiative for the Munich

API center together with Technische Universität München. The new center for API research and profiling will assist both institutions in de-veloping effective molecules and at the same time serve as platform for industrial cooperation with biotech and pharmaceutical companies. Clinical trials are the crucial step in successful drug development: The scientific idea must be tried and tested in proof-of-concept studies. Clinical cooperation groups and translational centers with competent medical partners enable a constant exchange between clinical and ba-sic research. Through this form of cooperation the Comprehensive Pneu-mology Center will make progress in the area of respiratory diseases and contribute with new insights to markedly improve health care. Internationally competitive research needs excellent scientists. For that reason, the support of the young generation of scientists is of spe-cial importance to us. The Graduate Student Program will improve the training and supervision of our circa 300 PhD students and will increase the attractiveness of our research campus.

One Center, One Goal

Our goal is to become the world’s leading research center in the field of environmental health by 2013. To achieve this goal, we have successfully repositioned ourselves in the past three years and have refined the focus of our research, which is to investigate the complex interactions between health and the environment. In our endeavor to benefit soci-ety, we seek to close knowledge gaps and make a major con-tribution to improving patients’ health and quality of life.

GOALS OF THE CENTER

Successful Scientific Research Requires Dependable StructuresScientists should have the freedom to focus entirely on their research, without having to worry about administrative matters. The responsibil-ity of the administration is to create a conducive work environment and framework conditions so that Helmholtz Zentrum München scientists can attain their research objectives. From this shared motivation, the scientists and the administrative staff develop synergies, define roles and tasks, and use modern and competitive instruments. With the optimization of our business processes we want to assist and support the core process: science. We have set in motion a struc-tural reorganization at Helmholtz Zentrum München: We are creating lean and transparent decision-making structures, streamlining bureau-cracy and are implementing decisions more quickly and effectively. In human resources development we are supporting the process of change and promoting an attractive work environment. Targeted business de-velopment is facilitating a faster and more efficient transfer of research results to applications. The development of a guiding principle for our center is creating an organizational culture oriented on common val-ues and is strengthening the identification of our employees with Helmholtz Zentrum München.

support processes

core processes

research in programs

knowledge and technology

transfer

training the young generation

of scientists

Coordination: Helmholtz Zentrum München

Program spokesperson: Martin Hrabé de Angelis

Participating center: Helmholtz Zentrum München

In 2008 Helmholtz Zentrum München applied for the second phase of program-oriented funding (POF II) of the Helmholtz Association with three strategic programs. Out of the six programs in the first phase of the funding (POF I), the Center developed three new strategic programs: »Environ-mental Health« and »Systemic Analysis of Multifactorial Diseases«, both in the research area of Health, and »Terrestrial Environment« in the area of Earth and the Environment. The programs re-sult from the new strategic orientation of the center on the theme Environmental Health. The sec-ond phase of the program-oriented funding runs for five years, from January 2009 until December 2013. The main emphasis of research in POF II is on disease: The focus in the program Environmental Health is primarily on lung diseases and reactions of the immune system to environmental diseases, for instance allergies and certain kinds of tumors. In »Systemic Analysis of Multifactorial Diseases«, diabetes and neurodegenerative diseases are the main focus. Cross-program projects in the areas of allergy, immunity and aerosol research represent interfaces between the program »Terrestrial Envi-ronment« and the area of health, in particular the program Environmental Health.

Systemic Analysis of Multifactorial Diseases

Multifactorial diseases have a great impact on the morbidity and mortality rates of a society. Im-portant examples of multifactorial diseases are neurodegenerative diseases such as Parkinson’s and Alzheimer’s, metabolic diseases such as diabetes and hypertension, or autoimmune diseases such as rheumatoid arthritis. They arise from the complex interaction of an individual genotype with environmental and lifestyle factors.

»The next great challenge for research will be to elucidate how genetic factors contribute to the development of multifactorial diseases and to determine what prerequisites and environmental conditions are necessary for systemic diseases to arise. Our goal is to analyze the key genetic fac-tors and biomolecular principles underlying multifactorial diseases.«

Research in ThreeStrategic Programs

Programs

Martin Hrabé de Angelis

Environmental Health

Environment-related diseases are among the great medical and socio-economic challenges for western society. The increasing life expectancy of the population and global changes in the envi-ronment will lead to a dramatic increase of diseases such as cardiovascular and respiratory dis-eases, cancer, allergies and diabetes, which develop from the complex interaction of environmen-tal factors, lifestyle and individual genetic disposition. Research in the program »Environmental Health« shall contribute to a better understanding of this interaction, in order to develop better prevention and early detection strategies for chronic diseases and to undertake new approaches to therapy. Helmholtz Zentrum München and the Helmholtz Centre for Environmental Research in Leipzig are cooperating in the Environmental Health program.

»We are investigating how environmental factors and genetic disposition interact in the develop-ment of chronic diseases, and from this we shall develop individualized strategies for prevention, early diagnosis and therapy.«

Terrestrial Environment – Strategies for a Sustainable Response to Climate and Global Change

Terrestrial systems are the setting where human activities drive global change and where in turn humans are directly affected in their living conditions and economic development. That is why terrestrial systems are the crucial point of departure for developing and implementing strategies for sustainable development. Research in the Helmholtz program »Terrestrial Environment« shall safeguard the natural basis of human life and health while simultaneously providing and shap-ing options for social and economic development. The program is coordinated by the Helmholtz Centre for Environmental Research – UFZ, Leipzig and carried out by the Helmholtz centers in Leipzig, Jülich (FZJ) and Munich.

»The program ›Terrestrial Environment‹ focuses on the idea of ecosystems services. The most im-portant question we face today is how to utilize the components soil, water and plants for the benefit of humans.«

Coordination: Helmholtz Zentrum München

Program spokesperson: Martin Göttlicher

Participating centers (in %):

Helmholtz Zentrum München (90%)

Helmholtz Centre for Environmental Research, Leipzig (10%)

Coordination: Helmholtz Centre for Environmental Research,

Leipzig

Program spokesperson: Bernd Hansjürgens, Leipzig

Program spokesperson: Jörg Durner, Helmholtz Zentrum München

Participating centers (in %):

Helmholtz Centre for Environmental Research , Leipzig (55 %)

Forschungszentrum Jülich (23 %)

Helmholtz Zentrum München (22 %)

Martin Göttlicher

Jörg Durner

POF PROGRAMS

Technology Transfer

Spin-off Companies of Helmholtz Zentrum München

Helmholtz Zentrum München is developing a broad spectrum of new competitive technologies. In cooperation with an external commercialization partner and via industrial partners, the results of our research shall be transferred as quickly as possible into novel applications.

In 2008, circa 40 ideas for inventions generated 20 priority-based patent applications. The patent portfolio was refined with respect to the commercialization prospects of the patent families and aligned with the strategic reorientation of Helmholtz Zentrum München. Of 122 patent families, 58 are currently in active commercialization and 25 are earmarked for licensing and planned spin-offs. Altogether, a total of 79 out-licensing contracts have been concluded. Besides commer-cialization through patents, the Center was able to move forward with the commercialization of non-patented know-how – here in particular the sale and licensing of antibodies. In 2008 the costs for 122 patent families amounted to circa 916,000 euros.

Sirenade Pharmaceuticals AG (www.keyneurotek.de) Taken over

by KeyNeurotek AG in 2005 – focus on neurodegenerative dis-

eases

MedTherm GmbH: Heat-shock for tumours Founded in 2008 –

hyperthermia as treatment method for cancer diseases

Vaecgene GmbH (www.vaecgene.de) Drugs for treatment of tu-

mor diseases and infectious diseases

Vivacs GmbH (www.emergentbiosolutions.com) In 2005 taken

over by Emergent BioSolutions including the rights to the vac-

cine vector technologies

TRION Pharma GmbH & TRION Research (www.trionpharma.de)

Founded in 1998 – trifunctional antibodies for the immunother-

apy of cancer diseases

ACTIVAERO GmbH (www.activaero.de) Founded under the name

of Inamed GmbH in 1998 – since 2006 the medical device devel-

opment division is Activaero GmbH – a competence center for

inhalation technology and aerosol medicine

Biomax Informatics AG (www.biomax.com) Founded in 1997–

develops software for the life science sector

Genomatix Software GmbH (www.genomatix.de) Founded in

1997 – programs for elucidating mechanisms and pathways in

biological systems

Inamed Research GmbH & Co. KG (www.inamed.de) Studies on

drug inhalation

Ingenium Pharmaceuticals GmbH (Probiodrug AG, www.pro-

biodrug.de) Investigates therapeutic approaches for inflamma-

tory diseases – integrated into Probiodrug AG in 2007

Isodetect GmbH (www.isodetect.de) Founded in 2005 – isotope

analyses in the environmental sector

In recent years Helmholtz Zentrum München has generated 10 spin-off companies, which have a total of 350 employees. In the beginning of 2008 MedTherm GmbH was added, a spin-off company founded by Prof. Dr. Rolf Issels, head of the Clinical Cooperation Group »Hyper-thermia« (together with Ludwig-Maximilians-Universität).

The first therapeutic antibody made in Germany is based on immuno-logical research conducted at Helmholtz Zentrum München (formerly GSF). The production method and the underlying effective principle of the antibody were developed, patented and out-licensed here in the mid-1990s. After successful conclusion of the clinical trials, the drug was developed to market maturity in the course of the last two years. Now, the European Medicines Agency EMEA has approved the antibody Catu-maxomab for the treatment of malignant ascites. The drug shall be brought to market under the name Removab. It is the world’s first ap-proved drug for the treatment of malignant ascites, an accumulation of fluid in the abdomen triggered by tumor diseases. Due to its trifunction-ality, the antibody is able to effectively destroy scattered tumor cells. The drug will be marketed by Fresenius Biotech GmbH. The manufactur-er is the partner company Trion Pharma GmbH, which was founded in 1998 as a spin-off of the present Helmholtz Zentrum München and today employs approximately 150 employees. Hence, Helmholtz Zentrum München is the cradle of a new genera-tion of immunotherapeutically active antibodies that can be targeted against cancer cells. The success story of the antibody is at the same time a confirmation of the technology transfer and translation model es-tablished at Helmholtz Zentrum München: Excellent basic research gen-erates results with high application potential. The further development

and ultimate transfer to clinical trials is facilitated by the close laborato-ry-hospital contact. Spin-offs and cooperations open up market poten-tial and facilitate development to market maturity. The licensing and the final commercialization process are competently guided and supported by the Center and a partner technology company. The Center receives a share in the value creation and revenues from licensing the research re-sults via the Life Science Foundation. The revenues flow back into the funding of innovative research projects. With this implementation strat-egy Helmholtz Zentrum München is involved in value creation in the biomedical sector. With the development of new therapies and innova-tive medicines, it is contributing – in line with the Helmholtz mission – to the solution of important social problems.

Removab – Model of Successful Value Creation

TECHNOLOGY TRANSFER

Trifunctional antibodies can additionally ac tivate the especially potent killer T cells.

accessory cell

T cellcancer cell

Equal OpportunityThe proportion of women scientists at Helmholtz Zentrum München in-creased between 2002 and 2008 (incl. postdocs and PhD students) from 37% to 47%. In grants for young scientists the proportion of women PhD students increased from 56% to 60%. For leadership positions the increase was even more striking – from 17% to 28%. In 2008 Helmholtz Zentrum München joined the Munich Dual Career Office of Technische Universität München. The Dual Career Office sup-ports women (and also men) in harmonizing career, mobility and family.

Human Resources Development and Further TrainingOur Human Resources Development Office offers target-group-specific measures and promotes career paths in administration and science. In 2008, 65 in-house further training events took place with 721 par-ticipants. The topics included modules on leadership and communica-tion as well as training seminars on science topics and methodology. In addition, 547 employees attended external courses in order to receive specialized training.

In 2008 there were 1956 employees at Helmholtz Zentrum München. 37% of their positions were financed by third-party funding. Circa half of the employees have fixed-term work contracts.

The majority of the staff works in the scientific area. Besides the technical staff there are 260 PhD students, 110 postdocs and 403 scientists employed primarily in the areas of biology, chemistry/biochemistry, physics and medicine. In 2008, as in other years, a wide array of apprenticeship positions was offered: Altogether 61 young people were being trained in the following profes-sions: biology laboratory assistant, animal keeper, office administrator, radiation protection engi-neer, IT specialist, warehouse specialist, agricultural assistant, industrial mechanic and energy electronics specialist. The majority of the trainees received a regular work contract after success-fully completing their training.

Staff

STAFF

Scientists’ disciplines

1. Biology/biotechnology/agricultural biology2. Chemistry/biochemistry3. Physics/biophysics4. Other disciplines5. Medicine6. Mathematics7. Engineering8. Informatics9. Geology/geophysics/geoecology10. Veterinary medicine

Vocational training disciplines 1. Biology laboratory assistant2. Industrial mechanic3. Animal keeper4. Energy electronics specialist5. Office administrator6. IT specialist7. Warehouse specialist8. Agricultural assistant9. Radiation protection engineer

Distribution of staff by area of work

1. Scientists2. Technical staff incl. infrastructure3. Administrative staff

79% =1

13% =2

8% =3

1 = 31%

2 = 18%

15% =

3

15% =4

8% =5

5% =6

3% =7

3% =8

2% =9

1 = 40%

16%

=2

11% =3

10% =4

7% =5

5% =6

4% =7

3% =8

2% =10

2% =9

The financial volume of Helmholtz Zentrum München amounted to ¤ 197.9 million in 2008, of which ¤ 96.5 million came from institutional funding and ¤ 101.4 million from third-party fund-ing. ¤ 32.8 million of this third-party funding was earmarked for supplementing the project-oriented research. The remaining third-party funds were remuneration for special tasks (oper-ation of Asse Mine, evaluation of radiation dosimeters).

Financial Development

Institutional funding 2008 total ¤ 96.47m thereof

1. Personnel costs ¤ 53.00 m 2. Material costs ¤ 22.96 m 3. Grants and subsidies to third parties ¤ 6.50 m4. Ongoing investments ¤ 12.80 m5. Construction/procurements > ¤ 2.5m ¤ 1.21 m

Overall financing 2008 total ¤ 197.87m thereof

1. Personnel costs ¤78.00 m 2. Material costs ¤ 75.59 m 3. Grants and subsidies to third parties ¤ 10.70 m4. Ongoing investments ¤32.37 m5. Construction/procurements > ¤ 2.5 m ¤1.21 m

0.61% =5

1.3% =5

54.9

% =

1

23.8% =2

6.7% =3

13.3% =4

1 = 39.42%

38.2% =2

5.41% =3

16.36% =4

FINANCIAL DEVELOPMENT

Third-party revenues according to source Research tasks total ¤ 32.8 m as of: May 25, 2009

1. Federal government project funding ¤12.8 m2. State government project funding ¤0.2 m3. German Research Foundation (DFG) ¤4.1 m4. Industry (national) ¤1.5 m5. Other (national) ¤4.1m6. EU ¤6.8 m7. Other European institutions ¤0.0 m8. Industry (international) ¤0.5 m9. Other (international) ¤2.9 m

Third-party revenues according to source Special tasks total ¤ 66.5 m as of: May 25, 2009

1. Asse Mine ¤60.5m2. Evaluation office ¤6.0 m

8.7% =9

1.4% =8

20.7% =6

12.4% =5

4.6%

=4

12.5

% =

3

1 = 39%2 = 0.7%

9% =2 91%

=1

Project Funding

Altogether, in the area of project funding Helmholtz Zentrum München had 410 research contracts in 2008. With a subsidy of ¤6.8 million and at present 73 ongoing contracts, EU funding comprises the largest por-tion of international funds raised. In public funding for Helmholtz Zentrum München, EU grants take second place, comprising almost 21% of the finance volume, immediately after the project funding by the Fed-eral Republic of Germany with 39 % and ahead of funding by the Ger-man Research Foundation (DFG) with 12.5 %. Helmholtz Zentrum München has participated in more than 170 grant applications in the 7th Framework Programme (FP7) of the Euro-pean Commission, of which 45 projects with EU funding amounting to more than ¤18 million were approved for the Center. With a grant of ¤1.6 million approved in 2008, Helmholtz Zentrum München is partner in the FP7 EMMAservice infrastructure with the task of building up and coordinating a European infrastructure institution for phenotyping and archiving mammalian model genomes. The aim is to make mouse mod-els for human diseases available to the biomedical research community. Vasilis Ntziachristos, director of the Institute of Biological and Medical Imaging and professor of Biological Imaging at Technische Universität München, received the ERC Advanced Grant 2008 for his planned re-search on multispectral optoacoustic tomography. Within the framework of the tender of the Initiative and Networking Fund of the Helmholtz As-

sociation, the Center was allocated a university junior research group and funding for two spin-off initiatives. In 2008, through the Life Science Foundation, the Center applied for and was awarded projects on Chemi-cal Biology with a financing volume of ¤1.65 million. Helmholtz Zentrum München is participating in research programs of the Federal Ministry of Education and Research in the Competence Network for Radiation Research and in a joint study with the two Mu-nich universities to investigate multimorbidity in over 65-year-olds, which is being funded with ¤2.6 million. In addition, the Center is a partner in the Competence Networks »Diabetes Mellitus« and »Adiposity«, for which it receives ¤1.6 million in funds. Helmholtz Zentrum München is an important partner of the follow-up programs of the National Genome Research Network (NGFN), funded by the Federal Ministry of Education and Research: Together with other Helmholtz centers it is participating with more than 28% of the total funding in the NGFN-Plus tender and in 2 NGFN-Transfer projects. In 2008 Helmholtz Zentrum München was allocated ¤11.2 million in NGFN-Plus funding.

Helmholtz Zentrum München demonstrates its compe t-itiveness through its successful participation in grant competitions of the Federal Ministry of Education and Research, the European Research Framework Programme, the German Research Foundation, the Helmholtz Associ-ation of German Research Centres and other public and private institutions.

PROJECT FUNDING

Important sources of funding for basic research at Helmholtz Zentrum München are the Deut-sche Forschungsgemeinschaft (German Research Foundation – DFG) funding programs, which to-taled ¤4.1 million in 2008. The Center is partici-pating in coordinated programs to form »excel-lence clusters« with German universities and is taking part in Collaborative Research Centers (German abbreviation: SFB) and Transregional Collaborative Research Centers (Transregio).

The German Mouse Clinic has many national and international coopera-tion agreements, e.g. with the University of Oxford, Jackson Laboratories, the University of Utah, Massachusetts General Hospital Corporation, Kuamoto University, the University of Uppsala and the University of Hel-sinki. In other research areas cooperation agreements exist with the In-ternational Atomic Energy Agency (IAEA), the International Commission on Radiological Protection (ICRP), the U.S. Environmental Protection Agency (EPA), the National Institutes of Health (NIH), the Health Protec-tion Agency and RIKEN Center for Developmental Biology in Japan and NACIS (Central Iron & Steel Research Institute). In 2008 Helmholtz Zentrum München was engaged in circa 1400 in-ternational cooperations with universities, non-university research in-stitutions and industrial partners in 59 countries throughout the world. These were a result of funding and cooperation agreements, bilateral exchanges between scientists during guest stays, and joint studies and publications. The U.S. and Canada are at the top of the list with respect to the number of international cooperation agreements. Within Europe, we cooperate mainly with partners in Great Britain, France, Italy, Aus-tria, Switzerland, Belgium and the Netherlands. Outside of Europe and North America, we cooperate primarily with partners in Japan, Russia, and China.

DFG Funding of Helmholtz Zentrum München in 2008 Funding program Projects

Individual funding 36Emmy Noether 2EURYI Award 1Leibniz Prize 1Research groups 79 Priority programs 116 Collaborative Research Centers and 3 Transregios 31

International Cooperation

Helmholtz Zentrum München – German Research Center for Environmental Health is a research institution of the Federal Republic of Germany and the Free State of Bavaria. It is a member of the Helmholtz Association of German Research Centres, the largest research organization in Germa-ny with 28,000 employees and an annual budget of 2.8 billion euros. The Center has existed since 1960 and since 1964 under the legal form of a GmbH (German limited liability company). The partners of Helmholtz Zentrum München are the Federal Republic of Germany, repre-sented by the Federal Minister of Education and Research, and the Free State of Bavaria, repre-sented by the Bavarian State Minister of Finance. The bodies of Helmholtz Zentrum München are the Assembly of Partners, the Supervisory Board, the Board of Directors and the Scientific and Technical Board. By appointing members to the Supervisory Board, the scientific and technical staff is also involved in fundamental decisions of the Center. On scientific questions, Helmholtz Zentrum München also obtains the advice of the Scientific Advisory Board, which consists of external members.

Organizational Structure

Supervisory Board

The Supervisory Board monitors the legality, appropriateness and

economic efficiency of the management. It makes decisions about

general research objectives and fundamental research policy is-

sues and financial matters, and lays down the basic principles for

performance control.

Members of the Supervisory Board MinDir Dr. Peter Lange – Chair –

Head of the Department of Health, Biosciences and

Sustainability, Federal Ministry of Education and Research

MinDirig Dr. Adalbert Weiß – Vice Chair –

Bavarian State Ministry of Sciences,

Research and the Arts

MinR Klaus HerzogBavarian State Ministry of Finance

MinDirig Dr. Karl Eugen HuthmacherFederal Ministry for the Environment, Nature

Conservation and Nuclear Safety

Dr. Arnd Kieser Gene Vectors Department, Helmholtz Zentrum München

Prof. Dr. Peter Schröder Microbe-Plant Interactions Department,

Helmholtz Zentrum München

Prof. Ruth Brack-Werner Institute of Virology, Helmholtz Zentrum München

RD Ulrich SchäfflerFederal Ministry of Education and Research

Dr. Martin SchölkopfFederal Ministry of Health, Head of Division,

Strategic Planning of Health Policy /Macroeconomic

Aspects of Public Health Care

ORGANIZATIONAL STRUCTURE

Dr. Nikolaus BlumCFO

Prof. Dr. Günther WessCEO and President

Members of the Scientific and Technical Board

Members of the Scientific Advisory Board

Members of the Board of Directors

Scientific and Technical Board

The Scientific and Technical Board advises the other bodies of

Helmholtz Zentrum München on all scientific and important

technical questions. Its members consist of the directors of the

institutes and heads of the departments as well as elected repre-

sentatives of the scientific and technical staff.

(As of: December 31, 2008)

Board of Directors

The Board Members are the legal representatives of Helmholtz

Zentrum München. They conduct business according to the Part-

nership Agreement, the resolutions of the Assembly of Partners

and the Supervisory Board.

Scientific Advisory Board

Advisory body to the Supervisory Board and the Board of Direc-

tors which evaluates the work of Helmholtz Zentrum München.

The Scientific Advisory Board was constituted in1984 with the

purpose of carrying on an intensive discussion about the scien-

tific programs and implementing an efficient result evaluation.

Dr. Joachim AltschuhProf. Dr. Michael Atkinson (Vice Chair)Dr. Laure Bally-CuifProf. Dr. Jörg DurnerProf. Dr. Oliver EickelbergDr. Bernhard FrankenbergerProf. Dr. Martin GöttlicherProf. Dr. Magdalena GötzProf. Dr. Wolfgang HammerschmidtProf. Dr. Anton HartmannProf. Dr. Heinz HöflerProf. Dr. Martin Hrabé de AngelisDr. Andrea Huber BrösamleDr. Christian KaiserDr. Arnd KieserProf. Dr. Rupert LasserProf. Dr. Rainer Meckenstock (Chair)Prof. Dr. Thomas MeitingerProf. Dr. Hans-Werner MewesDr. Gabriele Möller

Prof. Dr. Thomas BieberHospital and Outpatient Clinic of Dermatology,

University Hospital Bonn

Prof. Dr. Maria Blettner – Vice Chair –

Institute of Medical Biometry, Epidemiology

and Informatics, University of Mainz

Prof. Dr. Bernd DörkenMed. Clinic with a Focus on Oncology – Hematology –

Tumor Immunology, Charité University Medical Center

Campus Berlin-Buch

Prof. Dr. Martin H. GerzabekDepartment of Forest and Soil Sciences, Institute of Soil Research,

University of Natural Resources and Applied Life Sciences, Vienna

Prof. Dr. Wolfgang-Ulrich MüllerInstitute of Medical Radiation Biology,

University Hospital Essen

Prof. Dr. Dierk ScheelDepartment of Stress and Developmental Biology,

Leibniz Institute of Plant Biochemistry

Prof. Dr. Sylvia SchnellInstitute of Applied Microbiology, University of Giessen

Prof. Dr. Jean-Charles MunchProf. Dr. Vasilis NtziachristosProf. Dr. Herwig G. ParetzkeProf. Dr. Ulrike ProtzerDr. Uta von RadDr. Peter ReitmeirProf. Dr. Michael SattlerProf. Dr. Dolores SchendelProf Dr. Jörg SchmidtDr. Philippe Schmitt-KopplinDr. Felix SchöferProf. Dr. Peter SchröderDr. Sigurd Schulte-HostedeAndreas StampflDr. Tobias StögerDr. Marius UeffingProf. Dr. Dr. H.-Erich WichmannDr. Jana Barbro WinklerProf. Dr. Wolfgang WurstProf. Dr. Horst Zitzelsberger

Institute of Epidemiology (EPI) Director: Prof. Dr. Dr. H.-Erich Wich-

mann (LMU: Chair of Epidemiology) wichmann@helmholtz-

muenchen.de Institute of Health Economics and Health Care

Management (IGM) Director: Prof. Dr. Reiner Leidl (LMU: Chair of

Health Economics and Health Care Management) reiner.leidl@

helmholtz-muenchen.de Institute of Lung Biology and Disease

(iLBD) Director: Prof. Dr. Oliver Eickelberg (LMU: Chair of Experi-

mental Pneumology) oliver.eickelberg@helmholtz-muenchen.

de Institute of Molecular Radiation Biology (IMS) Director (act-

ing): PD Dr. Horst Zitzelsberger zitzelsberger@helmholtz-

muenchen.de Institute of Pathology (PATH) Director: Prof. Dr.

Heinz Höfler (TUM: Chair of Pathology and Pathological Anato-

my) [email protected] Institute of Radiation

Biology (ISB) Director: Prof. Dr. Michael Atkinson (TUM: Chair of

Radiation Biology) [email protected] Insti-

tute of Radiation Protection (ISS) Director (acting): Dr. Peter Ja-

cob [email protected] Institute of Toxicology

(TOXI) Director: Prof. Dr. Martin Göttlicher (TUM: Chair of Toxicol-

ogy and Environmental Hygiene) martin.goettlicher@helm-

holtz-muenchen.de Institute of Toxicology/Department of Cellu-

lar Signal Integration (AZS) Head: Dr. Daniel Krappmann dan-

[email protected] Institute of Bioinfor-

matics and Systems Biology (IBIS) Director: Prof. Dr. Werner

Mewes (TUM: Chair of Bioinformatics in Genomics) w.mewes

@helmholtz-muenchen.de Institute of Biomathematics and Bio-

metry (IBB) Director: Prof. Dr. Rupert Lasser (TUM: Chair of Bio-

mathematics) [email protected] Institute of

Biomathematics and Biometry/Department Scientific Computing

Head: Dr. Wolfgang Graf zu Castell-Rüdenhausen castell@

helmholtz-muenchen.de Institute of Developmental Genetics

(IDG) Director: Prof. Dr. Wolfgang Wurst (TUM: Chair of Develop-

mental Genetics) [email protected] Zebrafish

Neurogenetics Department (ZEN) Head: Dr. Laure Bally-Cuif

[email protected] Institute of Experimental Genet-

ics (IEG) Director: Prof. Dr. Martin Hrabé de Angelis (TUM: Chair

of Experimental Genetics) [email protected]

Institute of Experimental Genetics/Department Genome Analysis

Center (GAC) Head: Prof. Dr. Jerzy Adamski adamski@helm-

holtz-muenchen.de Institute of Human Genetics (IHG) Director:

Prof. Dr. Thomas Meitinger (TUM: Chair of Human Genetics)

[email protected] Protein Science Department

(PROT) Head: Dr. Marius Ueffing marius.ueffing@helmholtz-

muenchen.de Institute of Biological and Medical Imaging (IBMI)

Director: Prof. Dr. Vasilis Ntziachristos (TUM: Chair of Biological

Imaging) [email protected] Institute

of Stem Cell Research (ISF) Director: Prof. Dr. Magda lena Götz

(LMU: Chair of Physiological Genomics) magdalena.goetz@

helmholtz-muenchen.de Institute of Structural Biology (STB) Di-

rector: Prof. Dr. Michael Sattler (TUM: Chair of Biomolecular NMR

Spectroscopy) [email protected] Com parative

Medicine Department (AVM) Head: Prof. Dr. Jörg Schmidt jo-

[email protected] Institute of Clinical Mo-

lecular Biology and Tumor Genetics (KMOLBI) Director (acting):

Prof. Dr. Wolfgang Hammerschmidt hammerschmidt@helm-

holtz-muenchen.de Institute of Molecular Immunology (IMI) Di-

rector: Prof. Dr. Dolores Schendel schendel@helmholtz-

muenchen.de Institute of Virology (VIRO) Director: Prof. Dr. Ulrike

Protzer (TUM: Chair of Virology) protzer@helmholtz-muen-

chen.de Gene Vectors Department (AGV) Head: Prof. Dr. Wolf-

gang Hammerschmidt hammerschmidt@helmholtz-muenchen.

de Institute of Biochemical Plant Pathology (BIOP) Director: Prof.

Dr. Jörg Durner [email protected] Institute of

Soil Ecology (IBÖ) Director: Prof. Dr. Jean Charles Munch (TUM:

Chair of Soil Ecology) [email protected] Insti-

tute of Soil Ecology/Environmental Engineering Department

(EUS) Head: Dr. Harald Seidlitz harald.seidlitz @helmholtz-

muenchen.de Institute of Soil Ecology/Terrestrial Ecogenetics

Department (TEG) Head: Dr. Michael Schloter schloter@helm-

holtz-muenchen.de Institute of Groundwater Eco logy (IGOE) Di-

rector: Prof. Dr. Rainer Meckenstock (TUM: Chair of Groundwater

Ecology) rainer.meckenstock@helmholtz-muen chen.de Mi-

crobe-Plant Interactions Department (AMP) Director: Prof. Dr.

Anton Hartmann anton.hartmann@helmholtz-muen chen.de

Institute of Ecological Chemistry (IÖC) Director (acting): Dr. Si-

gurd Schulte-Hostede schuho@helmholtz-muen chen.de

As of: May 2009

Published by Helmholtz Zentrum München

German Research Center

for Environmental Health

Ingolstädter Landstr. 1

85764 Neuherberg

Germany

Phone: +49 (0)89 3187– 0

Fax: +49 (0)89 3187–3324

www.helmholtz-muenchen.de

Editorial Office Communication Department

Sven Winkler, Cordula Klemm,

Dr. Brigitte Keller,

Michael van den Heuvel

[email protected]

Translation Carol Oberschmidt, Berlin

www.c-l-s.net

Graphic Design & Layout Novamondo Design, Berlin,

www.novamondo.de

Printed by Das Druckteam Berlin,

www.druckteam-berlin.de

Novak Siebdruck, Berlin,

www.novak-siebdruck.de

Photos Martin Nink Fotografie, München,

www.ninkphoto.com, and

Ulla Baumgart, Michael Haggenmüller,

Frank Hisam, Jan Roeder, Michael

van den Heuvel, Novamondo Design

ISSN 0941-3847

Excerpts from the articles in this publication may be reproduced

without further permission, provided that Helmholtz Zentrum

München – German Research Center for Environmental Health

is mentioned. All other rights are reserved.

© Helmholtz Zentrum München 2009

Research Institutes and Departments

Imprint

and joint appointments with Ludwig-Maximilians-Universität Munich (LMU) and Technische Universität München (TUM)

The Helmholtz Association

The Helmholtz Association of German Research Centres is the largest scientific organization in Germany. Sixteen scientific-technical and biological-medical research centers have joined to-gether to make substantial contributions to basic scientific issues. With its staff of internationally renowned scientists, the Helm-holtz Association is using its potential to take an internationally leading position in all of its research areas to investigate com-plex scientific, social and economic issues with a holistic ap-proach and to offer appropriate solutions to identify solutions, working from the base up and translating them into applications to develop methods, technologies and services and to advise both policy-makers and society to contribute significantly to the effectiveness and appeal of the entire scientific system in Germany.

Helmholtz Zentrum MünchenGerman Research Center for Environmental Health

Ingolstädter Landstraße 1 D – 85764 NeuherbergTel: +49(0)89 3187– 0 Fax: +49(0)89 3187–3324www.helmholtz-muenchen.de

annual report

Documents

goal research

research programs

research location

hectare research campus

longterm research objectives

main areas of research

environmental health

helmholtz association